AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesInformation ScienceNamed GroupsHealth Care
Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic ProgressiveSclerosisAmyotrophic Lateral SclerosisEncephalomyelitis, Autoimmune, ExperimentalTuberous SclerosisDemyelinating DiseasesOptic NeuritisMyelin Basic ProteinMagnetic Resonance ImagingScleroderma, SystemicBrainOligoclonal BandsInterferon-betaMyelin SheathMyelin-Oligodendrocyte GlycoproteinSpinal CordDisability EvaluationMyelin ProteinsOligodendrogliaMyelin-Associated GlycoproteinNeuromyelitis OpticaDisease ProgressionCentral Nervous SystemMyelin Proteolipid ProteinAtrophyImmunologic FactorsHLA-DR2 AntigenEncephalomyelitis, Acute DisseminatedCuprizoneNerve Fibers, MyelinatedDiffuse Cerebral Sclerosis of SchilderCase-Control StudiesPropylene GlycolsDemyelinating Autoimmune Diseases, CNSDisease Models, AnimalTheilovirusSeverity of Illness IndexAxonsNervous System DiseasesRecurrenceAge of OnsetCerebrospinal FluidT-LymphocytesHLA-DRB1 ChainsCerebrospinal Fluid ProteinsMicrogliaOptic NerveAutoimmune DiseasesCardiovirus InfectionsNeurologic ExaminationRemission, SpontaneousFatigueAutoimmunityMice, Inbred C57BLBlood-Brain BarrierImmunosuppressive AgentsAstrocytesMethylprednisoloneEvoked Potentials, VisualAutoantibodiesScleroderma, DiffuseImmunoglobulin GHLA-DR AntigensTime FactorsGenetic Predisposition to DiseaseFollow-Up StudiesGadoliniumNeuritisAutoantigensNerve DegenerationMyelitis, TransverseImage EnhancementDisabled PersonsInflammationCentral Nervous System DiseasesCells, CulturedReproducibility of ResultsStatistics, NonparametricCorpus CallosumAdjuvants, ImmunologicCytokinesSpinal Cord DiseasesCohort StudiesMotor Neuron DiseaseScleroderma, LimitedEncephalomyelitisBiological MarkersSubacute Sclerosing PanencephalitisImage Processing, Computer-AssistedNeurofilament ProteinsRats, Inbred LewPeptidesTreatment OutcomeMeningesCD4-Positive T-LymphocytesLymphocyte ActivationCognition DisordersEncephalitis
Multiple Sclerosis
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
Multiple Sclerosis, Relapsing-Remitting
The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
Multiple Sclerosis, Chronic Progressive
A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)
Sclerosis
A pathological process consisting of hardening or fibrosis of an anatomical structure, often a vessel or a nerve.
Amyotrophic Lateral Sclerosis
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
Encephalomyelitis, Autoimmune, Experimental
An experimental animal model for central nervous system demyelinating disease. Inoculation with a white matter emulsion combined with FREUND'S ADJUVANT, myelin basic protein, or purified central myelin triggers a T cell-mediated immune response directed towards central myelin. The pathologic features are similar to MULTIPLE SCLEROSIS, including perivascular and periventricular foci of inflammation and demyelination. Subpial demyelination underlying meningeal infiltrations also occurs, which is also a feature of ENCEPHALOMYELITIS, ACUTE DISSEMINATED. Passive immunization with T-cells from an afflicted animal to a normal animal also induces this condition. (From Immunol Res 1998;17(1-2):217-27; Raine CS, Textbook of Neuropathology, 2nd ed, p604-5)
Tuberous Sclerosis
Autosomal dominant neurocutaneous syndrome classically characterized by MENTAL RETARDATION; EPILEPSY; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). There is, however, considerable heterogeneity in the neurologic manifestations. It is also associated with cortical tuber and HAMARTOMAS formation throughout the body, especially the heart, kidneys, and eyes. Mutations in two loci TSC1 and TSC2 that encode hamartin and tuberin, respectively, are associated with the disease.
Demyelinating Diseases
Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.
Optic Neuritis
Inflammation of the optic nerve. Commonly associated conditions include autoimmune disorders such as MULTIPLE SCLEROSIS, infections, and granulomatous diseases. Clinical features include retro-orbital pain that is aggravated by eye movement, loss of color vision, and contrast sensitivity that may progress to severe visual loss, an afferent pupillary defect (Marcus-Gunn pupil), and in some instances optic disc hyperemia and swelling. Inflammation may occur in the portion of the nerve within the globe (neuropapillitis or anterior optic neuritis) or the portion behind the globe (retrobulbar neuritis or posterior optic neuritis).
Myelin Basic Protein
An abundant cytosolic protein that plays a critical role in the structure of multilamellar myelin. Myelin basic protein binds to the cytosolic sides of myelin cell membranes and causes a tight adhesion between opposing cell membranes.
Magnetic Resonance Imaging
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
Scleroderma, Systemic
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
Brain
The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.
Oligoclonal Bands
Multiple protein bands serving as markers of specific ANTIBODIES and detected by ELECTROPHORESIS of CEREBROSPINAL FLUID or serum. The bands are most often seen during inflammatory or immune processes and are found in most patients with MULTIPLE SCLEROSIS.
Interferon-beta
One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity.
Myelin Sheath
The lipid-rich sheath surrounding AXONS in both the CENTRAL NERVOUS SYSTEMS and PERIPHERAL NERVOUS SYSTEM. The myelin sheath is an electrical insulator and allows faster and more energetically efficient conduction of impulses. The sheath is formed by the cell membranes of glial cells (SCHWANN CELLS in the peripheral and OLIGODENDROGLIA in the central nervous system). Deterioration of the sheath in DEMYELINATING DISEASES is a serious clinical problem.
Myelin-Oligodendrocyte Glycoprotein
A transmembrane protein present in the MYELIN SHEATH of the CENTRAL NERVOUS SYSTEM. It is one of the main autoantigens implicated in the pathogenesis of MULTIPLE SCLEROSIS.
Spinal Cord
A cylindrical column of tissue that lies within the vertebral canal. It is composed of WHITE MATTER and GRAY MATTER.
Disability Evaluation
Determination of the degree of a physical, mental, or emotional handicap. The diagnosis is applied to legal qualification for benefits and income under disability insurance and to eligibility for Social Security and workmen's compensation benefits.
Myelin Proteins
MYELIN-specific proteins that play a structural or regulatory role in the genesis and maintenance of the lamellar MYELIN SHEATH structure.
Oligodendroglia
A class of large neuroglial (macroglial) cells in the central nervous system. Oligodendroglia may be called interfascicular, perivascular, or perineuronal (not the same as SATELLITE CELLS, PERINEURONAL of GANGLIA) according to their location. They form the insulating MYELIN SHEATH of axons in the central nervous system.
Myelin-Associated Glycoprotein
A myelin protein found in the periaxonal membrane of both the central and peripheral nervous systems myelin sheaths. It binds to cells surface receptors found on AXONS and may regulate cellular interactions between MYELIN and AXONS.
Neuromyelitis Optica
A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.
Disease Progression
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Central Nervous System
The main information-processing organs of the nervous system, consisting of the brain, spinal cord, and meninges.
Myelin Proteolipid Protein
A myelin protein that is the major component of the organic solvent extractable lipoprotein complexes of whole brain. It has been the subject of much study because of its unusual physical properties. It remains soluble in chloroform even after essentially all of its bound lipids have been removed. (From Siegel et al., Basic Neurochemistry, 4th ed, p122)
Atrophy
Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
Immunologic Factors
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
HLA-DR2 Antigen
A broad specificity HLA-DR antigen that is associated with HLA-DRB1 CHAINS encoded by DRB1*01:15 and DRB1*01:16 alleles.
Encephalomyelitis, Acute Disseminated
An acute or subacute inflammatory process of the CENTRAL NERVOUS SYSTEM characterized histologically by multiple foci of perivascular demyelination. Symptom onset usually occurs several days after an acute viral infection or immunization, but it may coincide with the onset of infection or rarely no antecedent event can be identified. Clinical manifestations include CONFUSION, somnolence, FEVER, nuchal rigidity, and involuntary movements. The illness may progress to COMA and eventually be fatal. (Adams et al., Principles of Neurology, 6th ed, p921)
Cuprizone
Copper chelator that inhibits monoamine oxidase and causes liver and brain damage.
Nerve Fibers, Myelinated
A class of nerve fibers as defined by their structure, specifically the nerve sheath arrangement. The AXONS of the myelinated nerve fibers are completely encased in a MYELIN SHEATH. They are fibers of relatively large and varied diameters. Their NEURAL CONDUCTION rates are faster than those of the unmyelinated nerve fibers (NERVE FIBERS, UNMYELINATED). Myelinated nerve fibers are present in somatic and autonomic nerves.
Diffuse Cerebral Sclerosis of Schilder
A rare central nervous system demyelinating condition affecting children and young adults. Pathologic findings include a large, sharply defined, asymmetric focus of myelin destruction that may involve an entire lobe or cerebral hemisphere. The clinical course tends to be progressive and includes dementia, cortical blindness, cortical deafness, spastic hemiplegia, and pseudobulbar palsy. Concentric sclerosis of Balo is differentiated from diffuse cerebral sclerosis of Schilder by the pathologic finding of alternating bands of destruction and preservation of myelin in concentric rings. Alpers' Syndrome refers to a heterogeneous group of diseases that feature progressive cerebral deterioration and liver disease. (From Adams et al., Principles of Neurology, 6th ed, p914; Dev Neurosci 1991;13(4-5):267-73)
Case-Control Studies
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Propylene Glycols
Derivatives of propylene glycol (1,2-propanediol). They are used as humectants and solvents in pharmaceutical preparations.
Demyelinating Autoimmune Diseases, CNS
Conditions characterized by loss or dysfunction of myelin (see MYELIN SHEATH) in the brain, spinal cord, or optic nerves secondary to autoimmune mediated processes. This may take the form of a humoral or cellular immune response directed toward myelin or OLIGODENDROGLIA associated autoantigens.
Disease Models, Animal
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Theilovirus
A species of CARDIOVIRUS which contains three strains: Theiler's murine encephalomyelitis virus, Vilyuisk human encephalomyelitis virus, and Rat encephalomyelitis virus.
Severity of Illness Index
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
Axons
Nerve fibers that are capable of rapidly conducting impulses away from the neuron cell body.
Nervous System Diseases
Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.
Recurrence
The return of a sign, symptom, or disease after a remission.
Age of Onset
The age, developmental stage, or period of life at which a disease or the initial symptoms or manifestations of a disease appear in an individual.
Cerebrospinal Fluid
A watery fluid that is continuously produced in the CHOROID PLEXUS and circulates around the surface of the BRAIN; SPINAL CORD; and in the CEREBRAL VENTRICLES.
T-Lymphocytes
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
HLA-DRB1 Chains
A subtype of HLA-DRB beta chains that includes over one hundred allele variants. The HLA-DRB1 subtype is associated with several of the HLA-DR SEROLOGICAL SUBTYPES.
Cerebrospinal Fluid Proteins
Proteins in the cerebrospinal fluid, normally albumin and globulin present in the ratio of 8 to 1. Increases in protein levels are of diagnostic value in neurological diseases. (Brain and Bannister's Clinical Neurology, 7th ed, p221)
Microglia
The third type of glial cell, along with astrocytes and oligodendrocytes (which together form the macroglia). Microglia vary in appearance depending on developmental stage, functional state, and anatomical location; subtype terms include ramified, perivascular, ameboid, resting, and activated. Microglia clearly are capable of phagocytosis and play an important role in a wide spectrum of neuropathologies. They have also been suggested to act in several other roles including in secretion (e.g., of cytokines and neural growth factors), in immunological processing (e.g., antigen presentation), and in central nervous system development and remodeling.
Optic Nerve
The 2nd cranial nerve which conveys visual information from the RETINA to the brain. The nerve carries the axons of the RETINAL GANGLION CELLS which sort at the OPTIC CHIASM and continue via the OPTIC TRACTS to the brain. The largest projection is to the lateral geniculate nuclei; other targets include the SUPERIOR COLLICULI and the SUPRACHIASMATIC NUCLEI. Though known as the second cranial nerve, it is considered part of the CENTRAL NERVOUS SYSTEM.
Autoimmune Diseases
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
Cardiovirus Infections
Infections caused by viruses of the genus CARDIOVIRUS, family PICORNAVIRIDAE.
Neurologic Examination
Assessment of sensory and motor responses and reflexes that is used to determine impairment of the nervous system.
Remission, Spontaneous
A spontaneous diminution or abatement of a disease over time, without formal treatment.
Fatigue
The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
Autoimmunity
Process whereby the immune system reacts against the body's own tissues. Autoimmunity may produce or be caused by AUTOIMMUNE DISEASES.
Mice, Inbred C57BL
Blood-Brain Barrier
Specialized non-fenestrated tightly-joined ENDOTHELIAL CELLS with TIGHT JUNCTIONS that form a transport barrier for certain substances between the cerebral capillaries and the BRAIN tissue.
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Astrocytes
A class of large neuroglial (macroglial) cells in the central nervous system - the largest and most numerous neuroglial cells in the brain and spinal cord. Astrocytes (from "star" cells) are irregularly shaped with many long processes, including those with "end feet" which form the glial (limiting) membrane and directly and indirectly contribute to the BLOOD-BRAIN BARRIER. They regulate the extracellular ionic and chemical environment, and "reactive astrocytes" (along with MICROGLIA) respond to injury.
Methylprednisolone
A PREDNISOLONE derivative with similar anti-inflammatory action.
Evoked Potentials, Visual
The electric response evoked in the cerebral cortex by visual stimulation or stimulation of the visual pathways.
Autoantibodies
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Scleroderma, Diffuse
A rapid onset form of SYSTEMIC SCLERODERMA with progressive widespread SKIN thickening over the arms, the legs and the trunk, resulting in stiffness and disability.
Immunoglobulin G
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
HLA-DR Antigens
A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.
Time Factors
Elements of limited time intervals, contributing to particular results or situations.
Genetic Predisposition to Disease
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
Follow-Up Studies
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Gadolinium
Gadolinium. An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.
Neuritis
A general term indicating inflammation of a peripheral or cranial nerve. Clinical manifestation may include PAIN; PARESTHESIAS; PARESIS; or HYPESTHESIA.
Autoantigens
Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.
Nerve Degeneration
Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
Myelitis, Transverse
Inflammation of a transverse portion of the spinal cord characterized by acute or subacute segmental demyelination or necrosis. The condition may occur sporadically, follow an infection or vaccination, or present as a paraneoplastic syndrome (see also ENCEPHALOMYELITIS, ACUTE DISSEMINATED). Clinical manifestations include motor weakness, sensory loss, and incontinence. (Adams et al., Principles of Neurology, 6th ed, pp1242-6)
Image Enhancement
Improvement of the quality of a picture by various techniques, including computer processing, digital filtering, echocardiographic techniques, light and ultrastructural MICROSCOPY, fluorescence spectrometry and microscopy, scintigraphy, and in vitro image processing at the molecular level.
Disabled Persons
Persons with physical or mental disabilities that affect or limit their activities of daily living and that may require special accommodations.
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
Central Nervous System Diseases
Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
Cells, Cultured
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Reproducibility of Results
The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.
Statistics, Nonparametric
A class of statistical methods applicable to a large set of probability distributions used to test for correlation, location, independence, etc. In most nonparametric statistical tests, the original scores or observations are replaced by another variable containing less information. An important class of nonparametric tests employs the ordinal properties of the data. Another class of tests uses information about whether an observation is above or below some fixed value such as the median, and a third class is based on the frequency of the occurrence of runs in the data. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1284; Corsini, Concise Encyclopedia of Psychology, 1987, p764-5)
Corpus Callosum
Broad plate of dense myelinated fibers that reciprocally interconnect regions of the cortex in all lobes with corresponding regions of the opposite hemisphere. The corpus callosum is located deep in the longitudinal fissure.
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Cytokines
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
Spinal Cord Diseases
Pathologic conditions which feature SPINAL CORD damage or dysfunction, including disorders involving the meninges and perimeningeal spaces surrounding the spinal cord. Traumatic injuries, vascular diseases, infections, and inflammatory/autoimmune processes may affect the spinal cord.
Cohort Studies
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Motor Neuron Disease
Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)
Scleroderma, Limited
The least progressive form of SYSTEMIC SCLERODERMA with skin thickening restricted to the face, neck and areas distal to the elbows and/or knees, sparing the trunk. The CREST SYNDROME is a form of limited scleroderma.
Encephalomyelitis
A general term indicating inflammation of the BRAIN and SPINAL CORD, often used to indicate an infectious process, but also applicable to a variety of autoimmune and toxic-metabolic conditions. There is significant overlap regarding the usage of this term and ENCEPHALITIS in the literature.
Biological Markers
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
Subacute Sclerosing Panencephalitis
A rare, slowly progressive encephalitis caused by chronic infection with the MEASLES VIRUS. The condition occurs primarily in children and young adults, approximately 2-8 years after the initial infection. A gradual decline in intellectual abilities and behavioral alterations are followed by progressive MYOCLONUS; MUSCLE SPASTICITY; SEIZURES; DEMENTIA; autonomic dysfunction; and ATAXIA. DEATH usually occurs 1-3 years after disease onset. Pathologic features include perivascular cuffing, eosinophilic cytoplasmic inclusions, neurophagia, and fibrous gliosis. It is caused by the SSPE virus, which is a defective variant of MEASLES VIRUS. (From Adams et al., Principles of Neurology, 6th ed, pp767-8)
Image Processing, Computer-Assisted
A technique of inputting two-dimensional images into a computer and then enhancing or analyzing the imagery into a form that is more useful to the human observer.
Neurofilament Proteins
Type III intermediate filament proteins that assemble into neurofilaments, the major cytoskeletal element in nerve axons and dendrites. They consist of three distinct polypeptides, the neurofilament triplet. Types I, II, and IV intermediate filament proteins form other cytoskeletal elements such as keratins and lamins. It appears that the metabolism of neurofilaments is disturbed in Alzheimer's disease, as indicated by the presence of neurofilament epitopes in the neurofibrillary tangles, as well as by the severe reduction of the expression of the gene for the light neurofilament subunit of the neurofilament triplet in brains of Alzheimer's patients. (Can J Neurol Sci 1990 Aug;17(3):302)
Rats, Inbred Lew
Peptides
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
Treatment Outcome
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Meninges
The three membranes that cover the BRAIN and the SPINAL CORD. They are the dura mater, the arachnoid, and the pia mater.
CD4-Positive T-Lymphocytes
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Lymphocyte Activation
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
Cognition Disorders
Disturbances in mental processes related to learning, thinking, reasoning, and judgment.
Encephalitis
Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.
Leukoencephalopathy, Progressive Multifocal
An opportunistic viral infection of the central nervous system associated with conditions that impair cell-mediated immunity (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME and other IMMUNOLOGIC DEFICIENCY SYNDROMES; HEMATOLOGIC NEOPLASMS; IMMUNOSUPPRESSION; and COLLAGEN DISEASES). The causative organism is JC Polyomavirus (JC VIRUS) which primarily affects oligodendrocytes, resulting in multiple areas of demyelination. Clinical manifestations include DEMENTIA; ATAXIA; visual disturbances; and other focal neurologic deficits, generally progressing to a vegetative state within 6 months. (From Joynt, Clinical Neurology, 1996, Ch26, pp36-7)
Neuropsychological Tests
Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury.
Mice, Transgenic
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Slow Virus Diseases
Diseases of viral origin, characterized by incubation periods of months to years, insidious onset of clinical manifestations, and protracted clinical course. Though the disease process is protracted, viral multiplication may not be unusually slow. Conventional viruses produce slow virus diseases such as SUBACUTE SCLEROSING PANENCEPHALITIS, progressive multifocal leukoencephalopathy (LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL), and AIDS. Diseases produced by unconventional agents were originally considered part of this group. They are now called PRION DISEASES.
Cerebral Cortex
The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulchi. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions.
Brain Diseases
Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.
Brain Stem
The part of the brain that connects the CEREBRAL HEMISPHERES with the SPINAL CORD. It consists of the MESENCEPHALON; PONS; and MEDULLA OBLONGATA.
Muscle Spasticity
A form of muscle hypertonia associated with upper MOTOR NEURON DISEASE. Resistance to passive stretch of a spastic muscle results in minimal initial resistance (a "free interval") followed by an incremental increase in muscle tone. Tone increases in proportion to the velocity of stretch. Spasticity is usually accompanied by HYPERREFLEXIA and variable degrees of MUSCLE WEAKNESS. (From Adams et al., Principles of Neurology, 6th ed, p54)

Mental change as an early feature of multiple sclerosis. (1/4431)

Five patients with mental change as a prominent and early feature of an illness which appeared to be multiple sclerosis are reported. All the patients had in addition clinical signs of predominant brain stem involvement and the cerebrospinal fluid findings were similar. It is emphasised that mental change may be an early feature of multiple sclerosis even in those patients in whom the onset of the disease is insidious.  (+info)

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? (2/4431)

Brain-derived neurotrophic factor (BDNF) has potent effects on neuronal survival and plasticity during development and after injury. In the nervous system, neurons are considered the major cellular source of BDNF. We demonstrate here that in addition, activated human T cells, B cells, and monocytes secrete bioactive BDNF in vitro. Notably, in T helper (Th)1- and Th2-type CD4(+) T cell lines specific for myelin autoantigens such as myelin basic protein or myelin oligodendrocyte glycoprotein, BDNF production is increased upon antigen stimulation. The BDNF secreted by immune cells is bioactive, as it supports neuronal survival in vitro. Using anti-BDNF monoclonal antibody and polyclonal antiserum, BDNF immunoreactivity is demonstrable in inflammatory infiltrates in the brain of patients with acute disseminated encephalitis and multiple sclerosis. The results raise the possibility that in the nervous system, inflammatory infiltrates have a neuroprotective effect, which may limit the success of nonselective immunotherapies.  (+info)

Cortical lesions in multiple sclerosis. (3/4431)

Although previous studies have shown that the lesions of multiple sclerosis may involve the cerebral cortex, there is little published research on the prevalence and distribution of such lesions. Using neuropathological techniques and MRI, a series of studies has been undertaken in order to assess this, in particular to identify their relationship to cortical veins. A serial MRI study showed that the use of gadolinium proffered an increase in cortical lesion detection of 140% and showed that 26% of active lesions arose within or adjacent to the cortex. In a post-mortem study, MRI under-reported lesions subsequently analysed neuropathologically, particularly those arising within the cortex. In a further 12 cases examined, 478 cortical lesions were identified, of which 372 also involved the subcortical white matter. Seven different lesion types were identified; the majority arose within the territory of the principal cortical veins, whilst the remaining quarter arose within the territory of the small branch or superficial veins. Small cortical lesions are common in multiple sclerosis and are under-reported by MRI. Investigation of the cortical venous supply shows how such lesions may arise, and why the majority also involve the underlying white matter.  (+info)

The psychometric properties of clinical rating scales used in multiple sclerosis. (4/4431)

OullII;l y Many clinical rating scales have been proposed to assess the impact of multiple sclerosis on patients, but only few have been evaluated formally for reliability, validity and responsiveness. We assessed the psychometric properties of five commonly used scales in multiple sclerosis, the Expanded Disability Status Scale (EDSS), the Scripps Neurological Rating Scale (SNRS), the Functional Independence Measure (FIM), the Ambulation Index (AI) and the Cambridge Multiple Sclerosis Basic Score (CAMBS). The score frequency distributions of all five scales were either bimodal (EDSS and AI) or severely skewed (SNRS, FIM and CAMBS). The reliability of each scale depended on the definition of 'agreement'. Inter-and intra-rater reliabilities were high when 'agreement' was considered to exist despite a difference of up to 1.0 EDSS point (two 0.5 steps), 13 SNRS points, 9 FIM points, 1 AI point and 1 point on the various CAMBS domains. The FIM, AI, and the relapse and progression domains of the CAMBS were sensitive to clinical change, but the EDSS and the SNRS were unresponsive. The validity of these scales as impairment (SNRS and EDSS) and disability (EDSS, FIM, AI and the disability domain of the CAMBS) measures was established. All scales correlated closely with other measures of handicap and quality of life. None of these scales satisfied the psychometric requirements of outcome measures completely, but each had some desirable properties. The SNRS and the EDSS were reliable and valid measures of impairment and disability, but they were unresponsive. The FIM was a reliable, valid and responsive measure of disability, but it is cumbersome to administer and has a limited content validity. The AI was a reliable and valid ambulation-related disability scale, but it was weakly responsive. The CAMBS was a reliable (all four domains) and responsive (relapse and progression domains) outcome measure, but had a limited validity (handicap domain). These psychometric properties should be considered when designing further clinical trials in multiple sclerosis.  (+info)

Respiratory muscle involvement in multiple sclerosis. (5/4431)

Respiratory complications are common in the terminal stages of multiple sclerosis and contribute to mortality in these patients. When respiratory motor pathways are involved, respiratory muscle weakness frequently occurs. Although it is well established that weakness of the respiratory muscles produces a restrictive ventilatory defect, the degree of muscle weakness and pulmonary function are poorly related. Respiratory muscle weakness was observed in patients with normal or near normal pulmonary function. Expiratory muscle weakness is more prominent than inspiratory muscle weakness and may impair performance of coughing. Subsequently, in addition to bulbar dysfunction, respiratory muscle weakness may contribute to ineffective coughing, pneumonia, and sometimes even acute ventilatory failure may ensue. Respiratory muscle weakness may also occur early in the course of the disease. Recent studies suggest that the respiratory muscles can be trained for both strength and endurance in multiple sclerosis patients. Whether respiratory muscle training delays the development of respiratory dysfunction and subsequently improves exercise capacity and cough efficacy, prevents pulmonary complications or prolongs survival in the long-term remains to be determined.  (+info)

Non-coding plasmid DNA induces IFN-gamma in vivo and suppresses autoimmune encephalomyelitis. (6/4431)

Regulatory sequences used in plasmids for naked DNA vaccination can modulate cytokine production in vivo. We demonstrate here that injection of plasmid DNA can suppress the prototypic T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis, by inducing IFN-gamma.  (+info)

Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. (7/4431)

Metalloproteinases have been implicated in the pathogenesis of multiple sclerosis. We report longitudinal serum levels of gelatinase B and of the tissue inhibitors of matrix metalloproteinases (TIMP), TIMP-1 and TIMP-2, in 21 patients with relapsing multiple sclerosis. Patients had monthly clinical and gadolinium-enhanced MRI follow-up for 10 months. Longitudinal samples in nine healthy controls and cross-sectional samples from 12 patients with inflammatory CNS disease and 15 patients with other neurological diseases were used for comparison. Average serum gelatinase B, TIMP-1 and TIMP-2 levels were significantly higher in multiple sclerosis patients and those with other neurological diseases than in healthy controls. In the patients with multiple sclerosis, gelatinase B levels were significantly higher during clinical relapse compared with periods of clinical stability. Multiple sclerosis patients with high mean serum gelatinase B levels had significantly more T1-weighted gadolinium-enhancing MRI lesions than those with mean levels within the control range. TIMP-1 levels were not different during relapse and between relapses. There was a trend for TIMP-2 levels to be lower during relapse compared with non-relapse periods. For similar levels of serum gelatinase B, associated TIMP-1 levels were significantly lower and TIMP-2 levels significantly higher in multiple sclerosis patients compared with the inflammatory CNS control group. We propose that an abnormality in the inhibitory response to metalloproteinases may play an aetiological role in the chronicity of multiple sclerosis.  (+info)

A clinical study of motor evoked potentials using a triple stimulation technique. (8/4431)

Amplitudes of motor evoked potentials (MEPs) are usually much smaller than those of motor responses to maximal peripheral nerve stimulation, and show marked variation between normal subjects and from one stimulus to another. Consequently, amplitude measurements have low sensitivity to detect central motor conduction failures due to the broad range of normal values. Since these characteristics are mostly due to varying desynchronization of the descending action potentials, causing different degrees of phase cancellation, we applied the recently developed triple stimulation technique (TST) to study corticospinal conduction to 489 abductor digiti minimi muscles of 271 unselected patients referred for possible corticospinal dysfunction. The TST allows resynchronization of the MEP, and thereby a quantification of the proportion of motor units activated by the transcranial stimulus. TST results were compared with those of conventional MEPs. In 212 of 489 sides, abnormal TST responses suggested conduction failure of various degrees. By contrast, conventional MEPs detected conduction failures in only 77 of 489 sides. The TST was therefore 2.75 times more sensitive than conventional MEPs in disclosing corticospinal conduction failures. When the results of the TST and conventional MEPs were combined, 225 sides were abnormal: 145 sides showed central conduction failure, 13 sides central conduction slowing and 67 sides both conduction failure and slowing. It is concluded that the TST is a valuable addition to the study of MEPs, since it improves detection and gives quantitative information on central conduction failure, an abnormality which appears to be much more frequent than conduction slowing. This new technique will be useful in following the natural course and the benefit of treatments in disorders affecting central motor conduction.  (+info)

EARLY RELAPSES IN PATIENTS WITH HIGHLY ACTIVE MULTIPLE SCLEROSIS COMMENCED ON FINGOLIMOD; THE LEEDS TEACHING HOSPITAL...EARLY RELAPSES IN PATIENTS WITH HIGHLY ACTIVE MULTIPLE SCLEROSIS COMMENCED ON FINGOLIMOD; THE LEEDS TEACHING HOSPITAL...
Fingolimod is the much anticipated oral disease modifying treatment for patients with highly active Multiple sclerosis. A total of 42 patients were commenced on Fingolimod from December 2012 to June 2014 in Leeds Hospitals NHS Trust.. Four patients discontinued treatment due to patient choice, consecutive severe relapses and hepatotoxicity. No other severe side effects were noted in these 42 patients. A total of ten relapses were seen in nine patients. Of which eight out of ten relapses occurred within the first two months. Of the nine patients who experienced relapses, five (55%) were previously treated with Natalizumab, as opposed to four on injectable Disease Modifying Treatments (45%).. The five patients previously treated with Natalizumab all underwent a three month wash out period prior to commencing Fingolimod. The relapses all took place within the first two months following initiation of Fingolimod.. Early relapses in a patient group with highly active disease would suggest that a ...
https://jnnp.bmj.com/content/86/11/e4.28
Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. - Oxford Neuroscience
Imaging studies in multiple sclerosis have shown that spinal cord atrophy correlates with clinical disability. The pathological substrate of atrophy has not as yet been investigated adequately. In order to determine the cause of spinal cord atrophy in multiple sclerosis, five different sections of the spinal cord were examined histopathologically in 33 controls and 55 multiple sclerosis cases. In the multiple sclerosis cases in each section the total lesion load and the cross-sectional area of the cord were measured. Multiple regression models were estimated, controlling for sex, age, duration of the disease and location of the cord sections. The multiple sclerosis cords were found to be significantly smaller than the controls. The duration of the disease played the most important role in determining cord atrophy. The degree of atrophy varied in different parts of the cord. Individual lesions played a minor role in local atrophy. Our findings suggest that axonal degeneration, possibly caused by the
https://www.neuroscience.ox.ac.uk/publications/256421
Magnetic resonance imaging at first episode in pediatric multiple sclerosis retrospective evaluation according to KIDMUS and...Magnetic resonance imaging at first episode in pediatric multiple sclerosis retrospective evaluation according to KIDMUS and...
Background: Several diagnostic imaging criteria are being described and examined in pediatric multiple sclerosis (MS). Compared to adults, children are more likely to experience acute or relapsing demyelinating episodes of various etiologies which show similar clinical and magnetic resonance imaging (MRI) findings. Aim: To investigate the fulfillment of MRI diagnostic criteria at initial episode in pediatric MS. Methods: We reviewed our series of children and adolescents with the final diagnosis of clinically definite MS and applied the McDonald dissemination in space (DIS) and KIDMUS criteria to their initial MRI scans. Results: Thirty patients (17 girls, 13 boys), most with brainstem dysfunction and polysymptomatic presentation, were included in the study. Twenty-five (83.3%) patients fulfilled both McDonald and KIDMUS criteria. Patients who did not meet any McDonald DIS criteria did not meet KIDMUS criteria either. Only one patient met the McDonald criteria but not the KIDMUS criteria because ...
https://avesis.hacettepe.edu.tr/yayin/e3845b9c-bc2d-4eed-bfe9-7072ba361c2e/magnetic-resonance-imaging-at-first-episode-in-pediatric-multiple-sclerosis-retrospective-evaluation-according-to-kidmus-and-lesion-dissemination-in-space-criteria
Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis [Turk J Neurol]
Mira Ay en nsal. Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis. Turk J Neurol. 2019; 25(1): 50- ...
https://tjn.org.tr/jvi.aspx?pdir=tjn&plng=eng&un=TJN-00187
A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to...
PubMedID: 26280173 | A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity. | PloS one | 8/17/2015
https://www.docphin.com/research/article-detail/17763811/PubMedID-26280173/A-Longitudinal-Study-of-Disability-Cognition-and-Gray-Matter-Atrophy-in-Early-Multiple-Sclerosis-Patients-According-to-Evidence-of-Disease-Activity
PLOS ONE: Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple SclerosisPLOS ONE: Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis
Benign multiple sclerosis (BMS) occurs in about 15% of patients with relapsing-remitting multiple sclerosis (RRMS) that over time do not develop significant neurological disability. The molecular events associated with BMS are not clearly understood. This study sought to underlie the biological mechanisms associated with BMS. Blood samples obtained from a cohort of 31 patients with BMS and 36 patients with RRMS were applied for gene expression microarray analysis using HG-U133A-2 array (Affymetrix). Data were analyzed by Partek and pathway reconstruction was performed by Ingenuity for the most informative genes (MIGs). We identified a differing gene expression signature of 406 MIGs between BMS patients, mean±SE age 44.5±1.5 years, 24 females, 7 males, EDSS 1.9±0.2, disease duration 17.0±1.3 years, and RRMS patients, age 40.3±1.8 years, 24 females, 12 males, EDSS 3.5±0.2, disease duration 10.9±1.4 years. The signature was enriched by genes related RNA polymerase I (POL-1) transcription, general
http://journals.plos.org/plosone/article/related?id=10.1371/journal.pone.0046871
CMSC INforMS: MS treatment, faster MRI diagnosis method helps reduce brain inflammation - Consortium of Multiple Sclerosis...
Researchers from the University of Nottingham and Nottingham University Hospitals found a new way of using MRI scans to help detect the signs of multiple sclerosis in the brain. Multiple sclerosis can be difficult to diagnose as many do not experience symptoms for quite some time and symptoms may overlap with other conditions as well. MRI scans can be helpful in diagnosing multiple sclerosis at they can detect white matter lesions in the brain, but unfortunately these lesions do not always indicate multiple sclerosis.. The researchers found a way to use MRI scans to distinguish between lesions and other white spots in the brain which can be found in multiple sclerosis. The clinical MRI scanners can conduct a specific type of scan known as T2-weighted imaging, which can detect lesions in the brains white matter centered on a vein - a known indicator of multiple sclerosis.. Study lead Dr. Nikos Evangelou said, We already knew that large research MRI scanners could detect the proportion of ...
http://www.mscare.org/news/283119/Industry-News-for-MS-INforMS-CMSC-INforMS-MS-treatment-faster-MRI-diag.htm
Interleukin-9 regulates macrophage activation in the progressive multiple sclerosis brain | Journal of Neuroinflammation | Full...Interleukin-9 regulates macrophage activation in the progressive multiple sclerosis brain | Journal of Neuroinflammation | Full...
Multiple sclerosis (MS) is an immune-mediated, chronic inflammatory, and demyelinating disease of the central nervous system (CNS). Several cytokines are thought to be involved in the regulation of MS pathogenesis. We recently identified interleukin (IL)-9 as a cytokine reducing inflammation and protecting from neurodegeneration in relapsing-remitting MS patients. However, the expression of IL-9 in CNS, and the mechanisms underlying the effect of IL-9 on CNS infiltrating immune cells have never been investigated. To address this question, we first analyzed the expression levels of IL-9 in post-mortem cerebrospinal fluid of MS patients and the in situ expression of IL-9 in post-mortem MS brain samples by immunohistochemistry. A complementary investigation focused on identifying which immune cells express IL-9 receptor (IL-9R) by flow cytometry, western blot, and immunohistochemistry. Finally, we explored the effect of IL-9 on IL-9-responsive cells, analyzing the induced signaling pathways and functional
https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-020-01770-z/email/correspondent/c2/new
CMSC INforMS: Multiple sclerosis and the prevalence of sleep disorders, epileptic seizures - Consortium of Multiple Sclerosis...
Sleep disorders and epileptic seizures are of higher prevalence in those with multiple sclerosis. Multiple sclerosis is a chronic disease that affects the nervous system. Multiple studies have shown higher prevalence of other co-morbid disorders in those with multiple sclerosis, including sleep disorders and epileptic seizures.. One study conducted a large scale review of other research in regards to multiple sclerosis, sleep disorders and epileptic seizures. They evaluated 32 studies regarding seizures and 18 studies involving sleep disorders. Prevalence of seizures in multiple sclerosis patients was 2.28 percent and sleep disorders was 1.6 percent for narcolepsy, 14.5 - 57.5 percent for restless leg syndrome, 2.22 - 3.2 percent for REM behavior disorder and 7.14 - 58.1 percent for obstructive sleep apnea.. The review of the literature revealed that there are higher occurrences of sleep disorders and seizures in those with multiple sclerosis. The review acknowledged gaps in the research and ...
http://www.mscare.org/news/265055/CMSC-INforMS-Multiple-sclerosis-and-the-prevalence-of-sleep-disorders-epileptic-seizures.htm
NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple SclerosisNICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
First multiple sclerosis (MS) therapy to achieve positive NICE recommendation in the shortest possible timeframe Mavenclad has shown sustained
http://www.medindia.net/health-press-release/NICE-Recommends-Mavenclad-Cladribine-Tablets-for-Highly-Active-Multiple-Sclerosis-348129-1.htm
Imaging Techniques to Evaluate Morphological Correlates of Cognitive Dysfunction in Multiple Sclerosis Patients | Česká a...Imaging Techniques to Evaluate Morphological Correlates of Cognitive Dysfunction in Multiple Sclerosis Patients | Česká a...
1. Havrdová E. Roztroušená skleróza mozkomíšní. In: Havrdová E (ed). Neuroimunologie. 3rd ed. Praha: Maxdorf 2001: 231. 2. Benedict RH. Integrating cognitive function screening and assessment into the routine care of multiple sclerosis patients. CNS Spectr 2005; 10(5): 384-391. 3. Rao SM, Leo GJ, Bernardin L, Unverzang F. Cognitive dysfunction in multiple sclerosis. Frequency, patterns and prediction. Neurology 1991; 41(5): 685-691. 4. Jennekens-Schinkel A, Sanders EA. Decline of cognition in multiple sclerosis: dissociable deficits. J Neurol Neurosurg Psychiatry 1986; 49(12): 1354-1360. 5. Peyser JM, Edwards KR, Poser CM, Filskov SB. Cognitive function in patients with multiple sclerosis. Arch Neurol 1980; 37(9): 577-579. 6. Rao SM. Multiple sclerosis. In: Cummings JL (ed). Subcortical demention. New York: Oxford University Press 1990: 164-180. 7. Feldman RG, Albert ML, Willis AL. The subcortical dementia of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1974; 37(2): ...
https://www.csnn.eu/en/journals/czech-and-slovak-neurology-and-neurosurgery/2012-2-7/imaging-techniques-to-evaluate-morphological-correlates-of-cognitive-dysfunction-in-multiple-sclerosis-patients-37558
Multiple SclerosisMultiple Sclerosis
Multiple sclerosis is a disease of the central nervous system, brain, optic nerve, and spinal cord. In multiple sclerosis, the protective covering known as myelin that protects the nerves becomes damaged. Damaged myelin and damaged nerves disrupt the smooth flow of nerve impulses within the brain and between the brain, spinal cord, and body, causing the symptoms of multiple sclerosis. The areas of inflammation or damage that occur in the central nervous system are known as lesions or plaques.. Approximately 400,000 individuals have multiple sclerosis in the United States and 2.5 million worldwide. Most people are diagnosed with multiple sclerosis between the ages of 15 and 50. Women are more likely than men to develop the relapsing form of multiple sclerosis. Caucasians have a higher incidence of multiple sclerosis than those of African heritage. African Americans may experience more problems with vision and mobility. People living further from the Equator have a higher risk of multiple ...
http://neurologycenteroffairfax.com/specialties/multiple-sclerosis/
Multiple Sclerosis - HealthLibrary
1. Esparza ML, Sasaki S, Kesteloot H. Nutrition, latitude, and multiple sclerosis mortality: an ecologic study. Am J Epidemiol. 1995;142:733-737. 2. Lauer K. The risk of multiple sclerosis in the U.S.A. in relation to sociogeographic features: a factor-analytic study. J Clin Epidemiol. 1994;47:43-48. 3. Alter M, Yamoor M, Harshe M. Multiple sclerosis and nutrition. Arch Neurol. 1974;31:267-272. 4. Esparza ML, Sasaki S, Kesteloot H. Nutrition, latitude, and multiple sclerosis mortality: an ecologic study. Am J Epidemiol. 1995;142:733-737. 5. Swank RL. Multiple sclerosis: twenty years on low fat diet. Arch Neurol. 1970;23:460-474. 6. Swank RL, Dugan BB. Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet.1990;336:37-39. 7. Millar JH, Zilkha KJ, Langman MJ, et al. Double-blind trial of linoleate supplementation of the diet in multiple sclerosis. Br Med J. 1973;1:765-768. 8. Bates D, Fawcett PR, Shaw DA, et al. Polyunsaturated fatty acids in treatment of acute ...
http://healthlibrary.epnet.com/GetContent.aspx?token=6e1b4fd9-3088-4444-a0dd-dcb172e8624a&chunkiid=21789
METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING PULSE DOSE CALCITRIOL - Patent applicationMETHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING PULSE DOSE CALCITRIOL - Patent application
0007]The following references identify the numbers indicated above. [0008]1. Platten, M., and L. Steinman. 2005. Multiple sclerosis: trapped in deadly glue. Nature Medicine 11:252-253. [0009]2. Oksenberg, J. R., S. E. Baranzini, L. F. Barcellos, and S. L. Hauser. 2001. Multiple sclerosis: genomic rewards. Journal of neuroimmunology 113:171-184. [0010]3. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43:655-661. [0011]4. 1998. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352:1498-1504. [0012]5. Johnson, K. P., B. R. Brooks, J. A. Cohen, C. C. Ford, J. Goldstein, R. P. Lisak, L. W. Myers, H. S. Panitch, J. W. Rose, and R. B. Schiffer. ...
http://www.patentsencyclopedia.com/app/20090221538
Multiple Sclerosis | The Filipino Doctor | Health.Care - Philippines
Im sure you know a lot of people with diabetes. I can bet you have relatives diagnosed with hypertension. However, the chances are that you dont know anyone with multiple sclerosis.. After all, multiple sclerosis (MS) is thought to be relatively rare in the Philippines and in other tropical countries. Literally meaning numerous scars, it is an immunologic disorder of the central nervous system, characterized by the demyelination of axons and formation of plaques.. We cant let misconceptions about multiple sclerosis contribute to diagnostic and therapeutic difficulties! Its time to do a little myth-busting.. Myth #1: If someone in your family has it, youll have it, too. Having a family history of multiple sclerosis does not guarantee that one will get diagnosed with it later on.. Yes, the expert consensus on multiple sclerosis is that it comes with a genetic risk. Once exposed to the environmental triggers, someone genetically susceptible to MS may develop the disease.. Take note, ...
https://m.thefilipinodoctor.com/health-care/health-articles/542/
Multiple Sclerosis | 9781416550990 | comprar libro multiple sclerosis , venta libro , oferta | OfertonDeLibros.com
libro multiple sclerosis : The most trusted book on multiple sclerosis, updated and revised with the latest research in combating the disease.Once known as the crippler of young adults, now more than 75 percent of MS patients will never need a wheelchair. In Multiple Sclerosis, Dr. Louis J. Rosner and Shelley Ross explain that there genuinely is new hope, more than ever before, both for controlling the disease today and curing it tomorrow. Updated with the latest research and terminology, this revised edition gets to the bottom of every treatment option from the tried-and-true to todays cutting-edge and experimental therapies. Its trusted advice covers every step of living with MS, what you need to know, and what you need to ask. Dr. Louis Rosner and Shelley Ross explain what the disease is, who gets it and why, and what people with MS can do to continue living happy and healthy lives. Whether you or your loved one has just been diagnosed with MS or has lived with it for a while, Multiple Sclerosis
http://www.ofertondelibros.com/Libreria/Libro/Multiple-Sclerosis/_/R-9781416550990B
Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis. | Multiple Sclerosis Discovery Forum
All site content, except where otherwise noted, is licensed under a Creative Commons BY license. Please let us know where and how you use MSDF material ...
http://www.msdiscovery.org/papers/biblio/5072-cerebrospinal-fluid-fetuin-biomarker-active-multiple-sclerosis?qt-most_popular_papers=0
Multiple SclerosisMultiple Sclerosis
1. Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple scleoris. Am J Manage Care. 2013;19(2 Suppl): S15-20.. 2. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71(2): 129-135.. 3. Compston A, Coles A. Multiple sclerosis. The Lancet Neurology. 2008;372(9648): 1502-1517.. 4. Weiner HL. Multiple sclerosis is an inflammatory t-cell mediated autoimmune disease. Arch Neurol. 2004;61(10): 1613-1615.. 5. Bermel RA, Badshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. The Lancet Neurology. 2006;5(2): 158-170. 6. Resolution of Lhermittes sign in multiple sclerosis by treatment with weak electromagnetic fields. Int J Neurosci. 1995;81(3-4): 215-224. 7. Multiple sclerosis: Hope through research. National Institute of Neurological Disorders and Stoke. Available at: http://www.ninds.nih.gov/disorders/multiple_sclerosis/detail_multiple_sclerosis.htm. Accessed ...
https://www.pthaven.com/page/show/1079374
Lifesaving Drug For Multiple Sclerosis
The following article presents the very latest information on Multiple Sclerosis. If you have a particular interest in Multiple Sclerosis, then this informative article is required reading.. What the physicians think. Doctors at Liverpool have discovered a drug that can be considered as a miracle treatment for multiple sclerosis, a debilitating and muscle-wasting disease. The scientists held their research and tests at the Walton Neurological Centre and they claim that they have just heralded a breakthrough for the eighty-five thousand multiple sclerotic people in the United Kingdom.. Those who had multiple sclerosis, otherwise known as MS, who suffered from blindness, immobility and paralysis, have described the moments when they have eventually regained their ability to see and to walk again.. What the doctors used for treating such patients were a combination of mitoxantrone, which is a drug for chemotherapy, and copaxone, which is an anti-relapse medication of multiple sclerosis.. The ...
http://www.minolta-3d.com/multiple-sclerosis/lifesaving-drug-for-multiple-sclerosis.htm
Childbirth May Slow Multiple Sclerosis
The women who already have at least one child have a thirty-four percent less of the possibility of having a progressive state of multiple sclerosis. According to studies, those women who do not have children yet are more likely to reach a stage of MS where they would need assistance in walking with a brace or a cane.. Having a child before or after the symptoms of multiple sclerosis started to appear is of great help. On the other hand, those women who had children even after the onset of their disease?s symptoms were much better off. Either way, it seems that pregnancy helps in cases of multiple sclerosis. What the experts say. In fact, according to an expert from the Department of Neurology at the National MS Centrum which is located in Mesbroek, Belgium, named Marie D?hooghe, women who have multiple sclerosis and children tend to have a benign type of MS. This finding is in comparison to those women who have not yet given birth.. Research on multiple sclerosis indicates that eighty-five ...
http://www.minolta-3d.com/multiple-sclerosis/childbirth-may-slow-multiple-sclerosis.htm
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals...Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals...
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome. - Mark S Freedman
http://www.curehunter.com/public/pubmed25371710.do
Prospective 5-year study of benign multiple sclerosis | Медичний часописProspective 5-year study of benign multiple sclerosis | Медичний часопис
Benign multiple sclerosis (BMS) includes a triad of criteria: medium disability with the duration of the disease for |10 years while maintaining working - Медичний часопис
https://www.umj.com.ua/en/article/142088/prospective-5-year-study-of-benign-multiple-sclerosis
Multiple sclerosis susceptibility
Relief is when you and the right researcher find each other Finding the right clinical trial for Multiple sclerosis susceptibility can be challenging. However, with TrialsFinder (which uses the Reg4ALL database and privacy controls by Private Access), you can permit researchers to let you know opportunities to consider - all without revealing your identity. ...
http://www.diseaseinfosearch.org/result/8923
AAN Annual Meeting Programs: C190 - Multiple Sclerosis Overview III: Basic and Translational Science | American Academy of...
Improved management of multiple sclerosis (MS) would result from understanding of MS pathogenesis, risk factors, immune abnormalities, and mechanism of action of MS treatments, including understanding of complications that can result from those treatments. Faculty will discuss new understanding in MS pathogenesis and how immune interventions can alter disease pathogenesis for an improved clinical outcome, and the mechanism of action of current MS therapies. This program complements C201: Multiple Sclerosis Overview: Clinical Pearls and C214: Multiple Sclerosis Overview: Clinical Advances, but covers independent topics ...
https://tools.aan.com/annualmeeting/search/index.cfm?fuseaction=home.detail&id=5582&keyword=&topic=81&type=all
Magnetic resonance imaging of spinal cord lesions in multiple sclerosis. | Journal of Neurology, Neurosurgery & PsychiatryMagnetic resonance imaging of spinal cord lesions in multiple sclerosis. | Journal of Neurology, Neurosurgery & Psychiatry
The clinical and pathological manifestations of multiple sclerosis are due to areas of demyelination which occur throughout the white matter of the central nervous system. MRI of the brain frequently shows abnormalities in the hemispheric subcortical white matter; these are demonstrable in the majority of patients and support the clinical diagnosis of multiple sclerosis. Our studies have shown that while MRI identifies such cerebral lesions in nearly all clinically definite multiple sclerosis patients with illness of duration greater than 10 years, these areas of abnormal T2 signal are present less often in the brains of patients studied within 3 years of disease onset. However, symptoms referable to the long tracts of the spinal cord are prominent in many of these patients. Imaging of the spinal cord has presented technical problems because of the small size of the cord, patient body, heart and respiratory movements, and limitations of surface coil technology. The spinal cord of 77 patients ...
https://jnnp.bmj.com/content/52/4/459
Changed Histone Acetylation Patterns in Normal-Appearing White Matter and Early Multiple Sclerosis Lesions | Journal of...Changed Histone Acetylation Patterns in Normal-Appearing White Matter and Early Multiple Sclerosis Lesions | Journal of...
In this study, we analyzed the equilibrium between histone acetylation, mediated by HATs, and histone deacetylation, mediated by HDACs, in the NAWM of chronic MS brains. Similar to what was reported for the old rodent brain, also in the NAWM of human brains from aged individuals and chronic MS patients we detected a shift toward acetylation. This shift toward acetylation detected in a subset of female patients correlated with the consistent and reproducible increase of several histone acetyltransferase family members, including CBP, P300, MYST3, and MYST4. It is worth noting that, although we also detected increased levels of HDAC11 in this subpopulation, the increased of the acetyltransferases was much greater and likely determined the shift in favor of increased acetylation. These differences were most prominent in a subset of female MS patients and were associated with high levels of developmentally regulated genes (i.e., TCF7L2, SOX2, ID2) compared with controls. Several other genes (i.e., ...
http://www.jneurosci.org/content/31/9/3435.long
Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. - Nuffield Department of Obstetrics...
OBJECTIVE: To examine whether past high sun exposure is associated with a reduced risk of multiple sclerosis. DESIGN: Population based case-control study. SETTING: Tasmania, latitudes 41-3 degrees S. PARTICIPANTS: 136 cases with multiple sclerosis and 272 controls randomly drawn from the community and matched on sex and year of birth. MAIN OUTCOME MEASURE: Multiple sclerosis defined by both clinical and magnetic resonance imaging criteria. RESULTS: Higher sun exposure when aged 6-15 years (average 2-3 hours or more a day in summer during weekends and holidays) was associated with a decreased risk of multiple sclerosis (adjusted odds ratio 0.31, 95% confidence interval 0.16 to 0.59). Higher exposure in winter seemed more important than higher exposure in summer. Greater actinic damage was also independently associated with a decreased risk of multiple sclerosis (0.32, 0.11 to 0.88 for grades 4-6 disease). A dose-response relation was observed between multiple sclerosis and decreasing sun exposure when
https://www.obs-gyn.ox.ac.uk/publications/517424
Classification, diagnosis, and differential diagnosis of multiple sclerosis | LiveWiseMS
Acknowledgements. None.. Financial support and sponsorship. The research of I.K.S. is supported by the National Multiple Sclerosis Society, the United States Department of Defense, and the Guthy Jackson Charitable Foundation.. REFERENCES AND RECOMMENDED READING. Papers of particular interest, published within the annual period of review, have been highlighted as: * of special interest. ** of outstanding interest 1. Belbasis L, Bellou V, Evangelou E, et al. Environmental risk factors and multiple sclerosis: An umbrella review of systematic reviews and metaanalyses. Lancet Neurol 2015; 14:263-273.. 2. Sawcer S, Franklin RJ, Ban M. Multiple sclerosis genetics. Lancet Neurol 2014; 13:700-709.. 3. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology 1996; 46:907-911. 4. Kuceyeski AF, Vargas W, Dayan M, et al. Modeling ...
http://livewisems.org/resources/journal-articles/classification-diagnosis-and-differential-diagnosis-of-multiple-sclerosis
Novel SNARE Complex Polymorphisms Associated with Multiple Sclerosis: Signs of Synaptopathy in Multiple Sclerosis - Balkan...
Results: Significant differences were detected in the genotype and allele distribution of 26-bp Ins/Del polymorphisms of VAMP2 between patients with multiple sclerosis and control subjects; Del/Del genotype and Del allele of VAMP2 were more frequent in patients with multiple sclerosis (p=0.011 and p=0.004, respectively). Similarly, Ddel polymorphism of SNAP-25 gene C/C genotype (p=0.059), syntaxin 1A T/C and C/C genotypes (p=0.005), and synaptotagmin XI gene C allele (p=0.001) were observed more frequently in patients with multiple sclerosis. CC, syntaxin rs1569061 1A gene for 33-bp promoter region TC haplotypes, and synaptotagmin XI gene were found to be associated with an increased risk for multiple sclerosis (p=0.012). Similarly, GC haplotype for rs3746544 of SNAP-25 gene and rs1051312 of SNAP-25 gene were associated with an increased risk for multiple sclerosis (p=0.022 ...
http://balkanmedicaljournal.org/abstract.php?lang=en&id=2070
Lower Extremity Motor Evoked Potentials in Multiple Sclerosis<...
TY - JOUR. T1 - Lower Extremity Motor Evoked Potentials in Multiple Sclerosis. AU - Jones, Seth M.. AU - Streletz, Leopold. AU - Raab, Vicki E.. AU - Knobler, Robert L.. AU - Lublin, Fred D.. PY - 1991. Y1 - 1991. N2 - Transcranial magnetic stimulation was performed on 25 patients with definite multiple sclerosis. Motor evoked potentials were recorded from the anterior tibial muscle. Central motor conduction time was calculated using the equation (F + M-1)/2 by stimulation of the common peroneal nerve. Motor evoked potentials were capable of detecting subclinical pyramidal tract lesions in multiple sclerosis. In patients with multiple sclerosis, the incidence of abnormality of motor and somatosensory evoked potentials was similar. Central motor conduction time was correlated with overall and pyramidal tract subscores on the Kurtzke Disability Status Scale and the Scripps Neurological Rating Scale. Central motor conduction time abnormalities correlated best with the presence of a Babinskis sign ...
https://qfrd.pure.elsevier.com/en/publications/lower-extremity-motor-evoked-potentials-in-multiple-sclerosis
REbif FLEXible Dosing in Early Multiple Sclerosis (MS) - Tabular View - ClinicalTrials.govREbif FLEXible Dosing in Early Multiple Sclerosis (MS) - Tabular View - ClinicalTrials.gov
The study is a 24 months randomized, double-blind, Placebo-controlled, multi-center clinical trial with an optional 12 months open label extension.. The primary objective of the study is to evaluate the effect of fetal bovine serum [FBS]-free/human serum albumin [HSA]-free formulation of Interferon [IFN] beta-1a (RNF) 44 microgram (three times weekly and once weekly) versus placebo on the time to conversion to McDonald multiple sclerosis (MS) criteria (2005) in subjects with a first clinical demyelinating event at high risk of converting to MS.. The main secondary objective of study is to evaluate the effect of RNF 44 microgram (three times weekly and once weekly) versus placebo on the Time to conversion to clinically definite MS (CDMS) in subjects with a first clinical demyelinating event at high risk of converting to MS.. At the end of 24 month double-blind core REFLEX trial, subjects who will not convert to CDMS and decide to receive open-label (OL) treatment will be enrolled into an ...
https://clinicaltrials.gov/ct2/show/record/NCT00404352
Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?<...
TY - JOUR. T1 - Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?. AU - Rovaris, Marco. AU - Comi, Giancarlo. AU - Filippi, Massimo. PY - 2005/6/15. Y1 - 2005/6/15. N2 - The assessment of brain volume changes on serial magnetic resonance imaging (MRI) scans can provide an objective measure of progressive atrophy reflecting the neurodegenerative aspects of multiple sclerosis (MS) pathology. The present article reviews the results of studies assessing the effect of glatiramer acetate (GA) treatment in preventing MS-related, MRI-measurable brain volume decrease. Whilst data from the extended, open-label follow-up of the US trial seem to indicate that long-term treatment with GA might prevent the loss of brain parenchyma in relapsing-remitting MS patients, longitudinal data from the European/Canadian MRI trial suggest that, over a short-term period of treatment, GA does not have a clear-cut impact on the decrease of brain volume. The effect of GA on MS-related brain ...
https://moh-it.pure.elsevier.com/en/publications/can-glatiramer-acetate-reduce-brain-atrophy-development-in-multip
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis - Tabular View - ClinicalTrials.govStudy Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis - Tabular View - ClinicalTrials.gov
An SAE was defined as any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the subject at immediate risk of death (a life-threatening event; however, this does not include an event that, had it occurred in a more severe form, might have caused death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or results in a congenital anomaly/birth defect. An SAE may also have been any other medically important event that, in the opinion of the Investigator, may jeopardize the subject or may require intervention to prevent one of the other outcomes listed in the definition above. See Adverse Events section below for further details ...
https://clinicaltrials.gov/ct2/show/record/NCT01058005
Multiple Sclerosis: Causes - NatureWordMultiple Sclerosis: Causes - NatureWord
2) Infection. It has been theorized that multiple sclerosis can be caused by viral or bacterial infections. Over 90% of multiple sclerosis sufferers have bands of antibodies called immunoglobulins in the brain and spine fluid. These usually indicate the presence of an infectious agent to which the immune system has responded. These findings appear to indicate that an unknown or known, but unidentified virus or bacteria may trigger the onset of the disease. The theory is supported by the ability of some viruses to cause demyelination, or damage to the protective fatty myelin layer covering the tail of nerve cells.. 3) Geographical causes. Research shows an increase in multiple sclerosis cases in people living further from the equator, although exceptions exist. Northern Europeans, for example, appear to have a higher incidence of multiple sclerosis. Moreover, the disease appears to have an earlier onset in sufferers living in countries with little sunshine and cooler climates. The main ...
http://www.natureword.com/multiple-sclerosis-causes/
Download Advances in the Immunopathogenesis of Multiple Sclerosis by P. A. Muraro, A. Lugaresi, D. Gambi (auth.), D. Gambi, P....
Allegretta M, Nicklas JA, Sriram S, Albertini RJ (1990) T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247:718721 10. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA (1992) yo T cell receptor in acute multiple sclerosis lesions. Proc Nat! Acad Sci USA 89:4588-4592 11. Triebel F, Hercend T (1989) Subpopulations of human peripheral yo T lymphocytes. Immunol Today 10:186-188 12. Selmaj K, Brosnan CF, Raine CS (1991) Co-localization of lymphocytes bearing yo T cell receptor and heat shock protein hsp65+ oligodendrocytes in multiple sclerosis. Recent data indicate that glutamate released by electrically active neurons was indirectly involved in this inhibitory process and prevented MHC class II induction on microglia [13]. In our laboratory, glutamate (at lower concentrations, 20 flM) was found to reduce MHC class II inducibility of microglia in cultured brain tissue [13]. However, no direct effect of glutamate on isolated microglial cells ...
http://redecorayvende.com/lib/advances-in-the-immunopathogenesis-of-multiple-sclerosis
Predicting accidental falls in people with multiple sclerosis : a longitudinal studyPredicting accidental falls in people with multiple sclerosis : a longitudinal study
Objective: To investigate accidental falls and near fall incidents in people with multiple sclerosis with respect to clinical variables and the predictive values of four tests. Design: A longitudinal, multi-centred cohort study with prospectively collected falls. Procedures: Self-reported incidents during the three months following a standardized test procedure. Subjects: Seventy-six people with multiple sclerosis and an Expanded Disability Status Scale score between 3.5 and 6.0. Main outcome measures: Berg Balance Scale, Timed Up and Go cognitive, Four Square Step Test (FSST) and 12-item Multiple Sclerosis Walking Scale. Results: Forty-eight people (63%) registered 270 falls. Most falls occurred indoors during activities of daily life. We found a correlation of r(s) = 0.57 between near falls and falls, and of r(s) = 0.82 between registered and retrospectively recalled falls. Fallers and non-fallers differed significantly regarding Expanded Disability Status Score (odds ratio (OR) 1.99, 95% ...
http://mdh.diva-portal.org/smash/record.jsf?pid=diva2%3A159893&c=18&searchType=RESEARCH&language=no&query=&af=%5B%5D&aq=%5B%5B%7B%22personId%22%3A%22authority-person%3A30518%22%7D%5D%5D&aq2=%5B%5B%5D%5D&aqe=%5B%5D&noOfRows=50&sortOrder=author_sort_asc&sortOrder2=title_sort_asc&onlyFullText=false&sf=all
Interferon-γ induced increases in intracellular calcium in T lymphocytes from patients with multiple sclerosis precede...
Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis. Kuhle, Jens; Pohl, Christoph; Mehling, Matthias; Edan, Gilles; Freedman, Mark S.; Hartung, Hans-Peter; Polman, Chris H.; Miller, David H.; Montalban, Xavier; Barkhof, Frederik; Bauer, Lars; Dahms, Susanne; Lindberg, Raija; Kappos, Ludwig; Sandbrink, Rupert // New England Journal of Medicine;1/25/2007, Vol. 356 Issue 4, p371 Background: Patients with a single episode of neurologic dysfunction and brain magnetic resonance imaging (MRI) scans suggestive of multiple sclerosis are at high risk for clinically definite multiple sclerosis, but the outcome for individual patients is unpredictable. An increased risk of... ...
http://connection.ebscohost.com/c/articles/66329240/interferon-induced-increases-intracellular-calcium-t-lymphocytes-from-patients-multiple-sclerosis-precede-clinical-exacerbations-detection-active-lesions-mri
Treatment of Multiple Sclerosis, Multiple Sclerosis Definition, Causes, Risk Factors, Symptoms, Diagnosis & Treatment, Multiple...
Treatment of Multiple sclerosis (MS) is a chronic, potentially debilitating disease that affects your central nervous system, which is made up of your brain and spinal cord. Multiple sclerosis is widely believed to be an autoimmune disease, a condition in which your immune system attacks components of your body as if theyre foreign, In multiple sclerosis, the body mistakenly directs antibodies and white blood cells against proteins in the myelin sheath, a fatty substance that insulates nerve fibers in your brain and spinal cord. This results in inflammation and injury to the sheath and ultimately to the nerves that it surrounds. The result may be multiple areas of scarring (sclerosis). Eventually, this damage can slow or block the nerve signals that control muscle coordination, strength, sensation and vision, Multiple sclerosis affects an estimated 300,000 people in the United States and probably more than 1 million people around the world - including twice as many women as men. Most people experience
http://www.knowyourdisease.com/treatment-of-sclerosis-multiple.html
Highlight on Dr. Shiva Gopal Vasishtas Career and the Encouraging Results on Multiple Sclerosis Treatment - Alaska Bishop...
According to the results of a new clinical trial, stem cell transplants are likely to induce remission of multiple sclerosis in the long run. The trial indicates that high-dose immunosuppressive therapy and transplantation of an individuals own stem cells may stimulate sustained reduction of relapsing-remitting multiple sclerosis. After five years of receiving high-dose immunosupprresive therapy treatment and autologous hematopoietic cell transplant, 69 percent of the participants did not experience continued disability. Additionally, they did not suffer from progression of MS symptoms or a relapse. Noteworthy, after obtaining HDIT/HCT, participants did not take any medication. Some studies have noted that the success rates of the present MS drugs are lower.. The National Institute of Allergy and Infectious Diseases (NIAID) were the sponsors of the trial dubbed HALT-MS. Immune Tolerance Network, which is funded by NIAID, conducted the research. The researchers published both the initial ...
http://alaskabishopsearch.org/2017/02/17/highlight-on-dr-shiva-gopal-vasishtas-career-and-the-encouraging-results-on-multiple-sclerosis-treatment/
Vanishing Point: Product Marketplace: Poser Pro, Poser 7, Poser 6, Poser 5, Poser Pro Pack, Poser 4, Poser 8, Studio Max,...Vanishing Point: Product Marketplace: Poser Pro, Poser 7, Poser 6, Poser 5, Poser Pro Pack, Poser 4, Poser 8, Studio Max,...
Innovating the 3D World, we have content for Poser, Poser 5, Poser 6, Poser 7, Poser Pro, Poser 8, 3D Models, Poser model, Poser Models, Poser Clothes, Poser Clothing, Poser Props, Poser Downloads
https://www.vanishingpoint.biz/marketplace.asp?CategoryID=2&SubCategoryID=61
Multiple Sclerosis - Academic Association of MedicineMultiple Sclerosis - Academic Association of Medicine
Multiple Sclerosis is a type of demyelinating disease, a disease in which the nervous system is damaged by the deterioration of the outer layer of the neurons, called myelin. This phenomenon affects the transmission of the nerve impulses between neurons, which results in a variety of symptoms of multiple sclerosis, which may impair the sufferer to a certain degree. These symptoms may vary from physical, psychiatric and even mental issues. Specific symptoms of multiple sclerosis include double vision, weak muscles, and blindness in one or both eyes, difficulties with coordination or difficulties with sensations. Patients with multiple sclerosis usually experience one or more symptoms, in some cases these episodes being isolated. Between these episodes, the symptoms usually disappear completely. Nevertheless, the condition continues to develop, leaving permanent neurological damage, as the nerves continue to deteriorate. Up until the present time, the exact cause of multiple sclerosis remains ...
https://aaom.org/health/multiple-sclerosis/
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis<...Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis<...
TY - JOUR. T1 - Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. AU - Lock, Christopher. AU - Hermans, Guy. AU - Pedotti, Rosetta. AU - Brendolan, Andrea. AU - Schadt, Eric. AU - Garren, Hideki. AU - Langer-Gould, Annette. AU - Strober, Samuel. AU - Cannella, Barbara. AU - Allard, John. AU - Klonowski, Paul. AU - Austin, Angela. AU - Lad, Nagin. AU - Kaminski, Naftali. AU - Galli, Stephen J.. AU - Kaminski, Naftali. AU - Raine, Cedric S.. AU - Heller, Renu. AU - Steinman, Lawrence. PY - 2002/1/1. Y1 - 2002/1/1. N2 - Microarray analysis of multiple sclerosis (MS) lesions obtained at autopsy revealed increased transcripts of genes encoding inflammatory cytokines, particularly interleukin-6 and - 17, interferon-γ and associated downstream pathways. Comparison of two poles of MS pathologyacute lesions with inflammation versus silent lesions without inflammation-revealed differentially transcribed genes. Some products of these ...
https://einstein.pure.elsevier.com/en/publications/gene-microarray-analysis-of-multiple-sclerosis-lesions-yields-new-2
Stem Cell Transplantation in Multiple Sclerosis. | Multiple Sclerosis UW Rehabilitation ResearchStem Cell Transplantation in Multiple Sclerosis. | Multiple Sclerosis UW Rehabilitation Research
Objective: We are evaluating the therapeutic roles of high-dose immunosuppressive therapy (HDIT) rescued with autologous stem cell transplantation (SCT) in the management of patients with severe, nonresponsive multiple sclerosis (MS). Our hypothesis was that by ablating the immunoactive cells in a patient with MS and replacing them with nonconditional naïve cells, the disease process could be stopped. Design/Methods: We enrolled 26 patients with severe MS, including primary progressive MS (n = 7), secondary progressive MS (n = 18) and relapsing remitting MS (n = 1). Their median age was 41 years (range, 27-60). The median expanded disability status scale (EDSS) at HDIT was 7.0 (5.0-8.0). Eligibility requirements included an EDSS from 5.0 to 8.0 and deterioration of 1 or more points over the previous year. Twent-one patients had previous therapy with interferon-beta fail, and 15 had multiple therapies including Copaxone, prednisone, and methotrexate fail. The median follow-up was 12 months ...
http://msrrtc.washington.edu/node/178
Interferon Beta-1a Modulates the Innate Immune-response-mediated Regulation of Adaptive Immunity in Early Multiple Sclerosis ...Interferon Beta-1a Modulates the Innate Immune-response-mediated Regulation of Adaptive Immunity in Early Multiple Sclerosis ...
We performed Affymetrix gene arrays (HU133, ~38,500 genes) using RNA from the in vitro activated PBMCs from patients with clinically isolated syndrome suggestive of multiple sclerosis (CIS) (n=15) and matched healthy controls (HC) (n=8). Results were confirmed and further supported by RT-PCR and RayBio Cytokine Arrays. Affymetrix data revealed that IFNB-1a induced significant (p,0.05) up-regulation of 711, and down-regulation of 587 genes in CIS patients, and 446 and 543 in HC, respectively. CXCL11 and CXCL10, the ligands of CXCR3 were significantly increased in CIS patients and HC, whereas proinflammatory chemokines CXCL2, CXCL3 and CXCL5 were decreased in CIS patients. CCL18 and CCL19 were increased in CIS, while CCL22 and CCL17 were decreased in CIS and HC. Those chemokine gene changes reflect the complex effects of IFNB-1a that likely affect differentiation/ maturation and chemotaxis of DCs and other cells bridging the innate and adaptive immune response. The anti-inflammatory cytokine IL-10 ...
http://www.jimmunol.org/content/178/1_Supplement/S240.2
The Benefits Of Multiple Sclerosis Therapy | Photos for U
Multiple sclerosis is an inflammatory neurological disease that can generate a wide range of physical and psychological symptoms. Multiple sclerosis involves the deterioration of myelin, a substance that surrounds the bodys nervous cells. Myelin has a very important role in the transmission of nervous impulses, and if this substance is affected, the entire activity of the nervous system is seriously compromised. Although the actual causes of multiple sclerosis remain unknown, there are several hypotheses that present genetic abnormalities as the main factors responsible for causing the disease. Medical scientists believe that multiple sclerosis occurs on the background of inherited genetic predispositions, and environmental factors are suspected to be triggers of the disease. Some hypotheses also introduce viral infections in this scenario, although infections with viruses dont seem to contribute to the development of the disease. Multiple sclerosis can affect the body on different levels. The ...
http://photosfor.us/?p=885
Multiple Sclerosis. Multiple Sclerosis Help. Massage for Multiple Sclerosis. MS, MS Symptoms, MS Help Through Massage. The...
Multiple sclerosis. Multiple sclerosis help. Massage for multiple sclerosis. MS, MS symptoms, MS help through massage. The Haven Healing Centre. Complementary therapy in Bristol, Bath and North Somerset. Philip Chave, healer and therapist
http://www.thehavenhealingcentre.co.uk/multiple_sclerosis.htm
Primary Progressive Multiple Sclerosis Epidemiology Forecast by DelveInsight | ABNewswirePrimary Progressive Multiple Sclerosis Epidemiology Forecast by DelveInsight | ABNewswire
DelveInsight has launched a new report on Primary Progressive Multiple Sclerosis Epidemiology. Primary-progressive multiple sclerosis (PPMS) is a neurodegenerative disease that interferes with the brains ability to control the body. There are four main types of MS: relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS. Each type might be mild, moderate, or severe.. Request for free sample copy- https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-epidemiology-forecast Primary Progressive Multiple Sclerosis Epidemiology historical as well as forecasted Primary Progressive Multiple Sclerosis Epidemiology in the 7MM, covering the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan from 2018-2030. Primary Progressive Multiple Sclerosis Epidemiology PPMS can be further characterized at different points in time as either active (with an occasional relapse and/or ...
https://www.abnewswire.com/pressreleases/primary-progressive-multiple-sclerosis-epidemiology-forecast-by-delveinsight_529179.html
Primary Progressive Multiple Sclerosis (PPMS) Study of Brutons Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) |...Primary Progressive Multiple Sclerosis (PPMS) Study of Brutons Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) |...
Clinical trial for Dermatite Atopique modérée ou grave | Chronic progressive multiple sclerosis | Multiple Sclerosis | Radiologically Isolated Syndrome , Primary Progressive Multiple Sclerosis (PPMS) Study of Brutons Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
https://www.centerwatch.com/clinical-trials/listings/252879/primary-progressive-multiple-sclerosis-ppms-study-of-brutons-tyrosine-kinase-btk-inhibitor-tolebrutinib-sar442168/?&geo_lat=39.4269&geo_lng=-76.7769&radius=10&place=Owings%20Mills&user_country=United%20States&page=4&rnk=36
Chronic Cerebrospinal Venous Insufficiency (CCSVI) and Multiple Sclerosis (MS): A Critical Review | BenthamScienceChronic Cerebrospinal Venous Insufficiency (CCSVI) and Multiple Sclerosis (MS): A Critical Review | BenthamScience
Title: Chronic Cerebrospinal Venous Insufficiency (CCSVI) and Multiple Sclerosis (MS): A Critical Review. VOLUME: 10 ISSUE: 6. Author(s):Chiara Zecca and Claudio Gobbi. Affiliation:Servizio di Neurologia e Neuroradiologia, Neurocentro della Svizzera Italiana, Ospedale Regionale di Lugano, via esserete 46, 6903 Lugano, Switzerland.. Keywords:Chronic cerebrospinal venous insufficiency, MRI, Multiple Sclerosis, Pathogenesis, CCSVI, ECD, TCCD, MRI Venography, CCSVI Theory, Doppler sonography. Abstract: Multiple sclerosis (MS) is a chronic disease of the central nervous system with not yet completely understood pathogenesis. The so called chronic cerebrospinal venous insufficiency (CCSVI) theory has recently emerged, supporting the concept of a cerebrospinal venous drainage impairment as the cause of MS. Since the first publication on this topic with a claimed 100% specificity and sensitivity of the condition for MS diagnosis, CCSVI theory has generated a scientific and mass media debate with a ...
http://www.eurekaselect.com/94684/article
multiple sclerosis - Search | eLitMedmultiple sclerosis - Search | eLitMed
VÉCSEI László. [Recent data suggest that long-term worsening is common in relapsing-remitting multiple sclerosis patients and is largely independent of relapses or new lesion formation on brain MRI. The current definition of secunder progressive multiple sclerosis is worsening of disability independent of relapses over at least 6-month interval. Early focal inflammatory disease activity and spinal cord lesion are predictors of very-long term disease outcomes in relapse - onset multiple sclerosis. The potential of PET imaging to visualize hidden inflammation in MS brain in vivo is an important contribution for better understanding the progression of the disease. Therefore, PET imaging is a promising tool in detecting the conversion from relapsing remitting multiple sclerosis to secunder progressive form of multiple sclerosis. Furthermore, neuro-axonal damage is the pathological substrate of permanent disability in different neurological disorders including multiple sclerosis. The neurofilament ...
https://elitmed.hu/en/search?s=multiple+sclerosis
Stem Cell Therapy: Modern Medicines Promising Future For MS Treatment - Multiple Sclerosis News TodayStem Cell Therapy: Modern Medicines Promising Future For MS Treatment - Multiple Sclerosis News Today
Additional evidence comes from a group of researchers and clinicians from the United Kingdom who treated MS patients in the study, Autologous Mesenchymal Stem Cells for the Treatment of Secondary Progressive Multiple Sclerosis: An Open-Label Phase 2a Proof-of-Concept Study.. Research findings show that intravenous administration of autologous mesenchymal stem cells to patients with secondary progressive multiple sclerosis is feasible and safe and suggests structural, functional, and physiological improvement in patients after receiving treatment with autologous mesenchymal stem cells which is consistent with remyelination. In addition, patients experienced enhanced visual acuity.. Dr. Andre Lallande, Medical Director of StemGenex Medical Group and Principal Investigator of the observational study Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis, evaluates the quality of life changes measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI) in individuals following ...
https://multiplesclerosisnewstoday.com/2016/05/03/stem-cell-therapy-modern-medicines-promising-future-ms-treatment/
IPBiz: Novantrone for secondary progressive multiple sclerosisIPBiz: Novantrone for secondary progressive multiple sclerosis
The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of mitoxantrone, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, mitoxantrone and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. Additionally, the subject invention provides a pharmaceutical composition comprising an amount of glatiramer acetate and an amount of mitoxantrone, wherein the amounts when taken together are effective to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of ...
http://ipbiz.blogspot.com/2016/04/novantrone-for-secondary-progressive.html
Physiotherapy rehabilitation for people with progressive Multiple Sclerosis: a systematic review<...Physiotherapy rehabilitation for people with progressive Multiple Sclerosis: a systematic review<...
TY - JOUR. T1 - Physiotherapy rehabilitation for people with progressive Multiple Sclerosis: a systematic review. AU - Campbell, Evan. AU - Coulter, Elaine. AU - Mattison, Paul G.. AU - Miller, Linda. AU - McFadyen, Angus. AU - Paul, Lorna. PY - 2016/1. Y1 - 2016/1. N2 - ObjectiveTo assess the efficacy of physiotherapy interventions, including exercise therapy, for the rehabilitation of people with progressive multiple sclerosis.Data SourcesFive databases (Cochrane Library, Physiotherapy Evidence Database [PEDro], Web of Science Core Collections, MEDLINE, Embase) and reference lists of relevant articles were searched.Study SelectionRandomized experimental trials, including participants with progressive multiple sclerosis and investigating a physiotherapy intervention or an intervention containing a physiotherapy element, were included.Data ExtractionData were independently extracted using a standardized form, and methodologic quality was assessed using the PEDro scaleData SynthesisThirteen ...
https://researchonline.gcu.ac.uk/en/publications/physiotherapy-rehabilitation-for-people-with-progressive-multiple
Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving...
TY - JOUR. T1 - Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a. T2 - Results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II). AU - Patti, Francesco. AU - Amato, Maria Pia. AU - Trojano, Maria. AU - Bastianello, Stefano. AU - Tola, Maria Rosalia. AU - Picconi, Orietta. AU - Cilia, Sabina. AU - Cottone, Salvatore. AU - Grimaldi, Luigi M E. PY - 2012/9. Y1 - 2012/9. N2 - Purpose To report longitudinal changes in and explore the influence of cognition on social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS). Methods Italian patients (18-50 years) with RRMS and Expanded Disability Status Scale (EDSS) score ≤4.0 were assigned to interferon β-1a, 44 or 22 μg subcutaneously three times weekly, and underwent annual assessments for social functioning (Environmental Status Scale [ESS]) over 3 years. Results Baseline total ESS ...
https://moh-it.pure.elsevier.com/en/publications/longitudinal-changes-in-social-functioning-in-mildly-disabled-pat
Defining secondary progressive multiple sclerosis - DRODefining secondary progressive multiple sclerosis - DRO
Lorscheider, Johannes, Buzzard, Katherine, Jokubaitis, Vilija, Spelman, Tim, Havrdova, Eva, Horakova, Dana, Trojano, Maria, Izquierdo, Guillermo, Girard, Marc, Duquette, Pierre, Prat, Alexandre, Lugaresi, Alessandra, GrandMaison, Francois, Grammond, Pierre, Hupperts, Raymond, Alroughani, Raed, Sola, Patrizia, Boz, Cavit, Shaw, Cameron and Barnett, Michael H. 2016, Defining secondary progressive multiple sclerosis, Brain a journal of neurology, vol. 139, no. 9, pp. 2395-2405, doi: 10.1093/brain/aww173. ...
http://dro.deakin.edu.au/view/DU:30099548
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe...Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe...
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology / Owain, Howell ...
https://cronfa.swan.ac.uk/Record/cronfa16585
PRIME PubMed | TNFRSF1A polymorphisms and their role in multiple sclerosis susceptibility and severity in the Slovak populatioPRIME PubMed | TNFRSF1A polymorphisms and their role in multiple sclerosis susceptibility and severity in the Slovak populatio
PubMed journal article TNFRSF1A polymorphisms and their role in multiple sclerosis susceptibility and severity in the Slovak populatio were found in PRIME PubMed. Download Prime PubMed App to iPhone or iPad.
https://www.unboundmedicine.com/medline/citation/30009568/TNFRSF1A_polymorphisms_and_their_role_in_multiple_sclerosis_susceptibility_and_severity_in_the_Slovak_population_
Tisas MS Liberation Experience: How long have Dr.s known about Iron in the brain? Thanks Joan for this infoTisas MS Liberation Experience: How long have Dr.s known about Iron in the brain? Thanks Joan for this info
SUMMARY Evidence of damage to cerebral vein walls was sought in 70 cases of multiple sclerosis. Seventy control cases were also examined. The multiple sclerosis cases showed venous intramural fibrinoid deposition (7 %), recent haemorrhages (17%), old haemorrhages revealed by haemosiderin deposition (30%), thrombosis (6%) and thickened veins (19%). In all, 41% of all multiple sclerosis cases showed some evidence of vein damage. Occasional control cases showed haemosiderin deposition in the brain but, unlike the multiple sclerosis cases, these were diffuse and almost entirely related to coexistent cardiovascular or cerebrovascular disease. Haemosiderin deposition was common in the substantia nigra and other pigmented nuclei in all cases. It is concluded that the cerebral vein wall in multiple sclerosis is subject to chronic inflammatory damage, which promotes haemorrhage and increased permeability, and constitutes a form of vasculitis ...
http://tisasmsliberationexperience.blogspot.com/2010/05/how-long-have-drs-known-about-iron-in.html
multiple sclerosis medicine | ayurvedic medicine for multiple sclerosismultiple sclerosis medicine | ayurvedic medicine for multiple sclerosis
Buy ayurvedic medicine for multiple sclerosis, herbal medicine for multiple sclerosis with wide range of multiple sclerosis medicine and best medicine for multiple sclerosis, ayurvedic treatment for multiple sclerosis
https://www.ayurvikalp.com/subsection/Multiple-Sclerosis
Multiple Sclerosis Drug First of Its Kind, Treats Progressive Form of the DiseaseMultiple Sclerosis Drug First of Its Kind, Treats Progressive Form of the Disease
According to a report from Scientific American, just this past September, pharmaceutical company Hoffmann-La Roche announced they achieved positive results from three large clinical trials of a drug called Ocrelizumab,. It is an injectable antibody medication that targets the bodys B cells, and works for both relapsing and progressive multiple sclerosis.. Up until this point, most patients have received the best results with a drug called interferon beta-1a. Ocrelizumab is believed to be even more effective. Even better, it also slowed the advance of symptoms in patients with progressive multiple sclerosis.. Dr. Stephen Hauser is a neurologist at the University of California, San Francisco. He was involved in the trials.. The drug has dramatic effects on relapsing MS, and we finally have our foot in the door with the progressive form, he says.. Scientists working on the root causes of multiple sclerosis are excited about the may Ocrelizumab works on those with the disease. ...
https://www.webpronews.com/multiple-sclerosis-drug-first-of-its-kind-treats-progressive-form-of-the-disease-2015-12/
Multiple Sclerosis Drug First of Its Kind, Treats Progressive Form of the DiseaseMultiple Sclerosis Drug First of Its Kind, Treats Progressive Form of the Disease
According to a report from Scientific American, just this past September, pharmaceutical company Hoffmann-La Roche announced they achieved positive results from three large clinical trials of a drug called Ocrelizumab,. It is an injectable antibody medication that targets the bodys B cells, and works for both relapsing and progressive multiple sclerosis.. Up until this point, most patients have received the best results with a drug called interferon beta-1a. Ocrelizumab is believed to be even more effective. Even better, it also slowed the advance of symptoms in patients with progressive multiple sclerosis.. Dr. Stephen Hauser is a neurologist at the University of California, San Francisco. He was involved in the trials.. The drug has dramatic effects on relapsing MS, and we finally have our foot in the door with the progressive form, he says.. Scientists working on the root causes of multiple sclerosis are excited about the may Ocrelizumab works on those with the disease.. ...
https://www.webpronews.com/multiple-sclerosis-drug-first-of-its-kind-treats-progressive-form-of-the-disease/
A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. - Department of PharmacologyA type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. - Department of Pharmacology
OBJECTIVE: We tested whether it is possible to differentiate relapsing-remitting (RR) from secondary progressive (SP) disease stages in patients with multiple sclerosis (MS) using a combination of nuclear magnetic resonance (NMR) metabolomics and partial least squares discriminant analysis (PLS-DA) of biofluids, which makes no assumptions on the underlying mechanisms of disease. METHODS: Serum samples were obtained from patients with primary progressive MS (PPMS), SPMS, and RRMS; patients with other neurodegenerative conditions; and age-matched controls. Samples were analyzed by NMR and PLS-DA models were derived to separate disease groups. RESULTS: The PLS-DA models for serum samples from patients with MS enabled reliable differentiation between RRMS and SPMS. This approach also identified significant differences between the metabolite profiles of each of the MS groups (PP, SP, and RR) and the healthy controls, as well as predicting disease group membership with high specificity and sensitivity.
https://www.pharm.ox.ac.uk/publications/485211
Primary progressive multiple sclerosis and severe pains, responding to PEA | palmitoylethanolamide4pain
A 54 year old female patient, born in 1959, was diagnosed suffering from primary progressive multiple sclerosis more than 10 years ago, and retrospectively symptoms started already in 1992. She underwent various operations (3 times) to correct a fixed kyphosis and 2 years ago started to suffer from increasing pains and muscle spasms. She was…
https://palmitoylethanolamide4pain.com/2013/07/07/primary-progressive-multiple-sclerosis-and-severe-pains-responding-to-pea/
Intensive Directed Nutrition And Neuromuscular Electrical Stimulation In The Setting Of Secondary Progressive Multiple...Intensive Directed Nutrition And Neuromuscular Electrical Stimulation In The Setting Of Secondary Progressive Multiple...
Digital Download Price: $20 [purchase_link id=696 style=button color=blue text=Download Immediately price=0 direct=true] Intensive Directed Nutrition And Neuromuscular Electrical Stimulation In The Setting Of Secondary Progressive Multiple Sclerosis - Allied Health Professionals Version Dr. Terry Wahls has secondary progressive multiple sclerosis and spent nearly four years dependent upon a tilt-recline wheelchair. An accomplished internal medicine physician, […]
https://terrywahls.com/intensive-directed-nutrition-and-neuromuscular-electrical-stimulation-in-the-setting-of-secondary-progressive-multiple-sclerosis-allied-health-professionals-version-digital/
FDA Approved Drug Treatment for Multiple Sclerosis Patients Now Available at Hackensack Meridian Health Hackensack University...FDA Approved Drug Treatment for Multiple Sclerosis Patients Now Available at Hackensack Meridian Health Hackensack University...
Hackensack Meridian Health Hackensack University Medical Center announced a newly approved U.S. Food and Drug Administration drug is now available to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). The drug, Ocrevus, which received FDA approval on March 28th, is the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis.. Click here to view the full article on njbmagazine.com. ...
https://www.hackensackumc.org/2017/05/19/fda-approved-drug-treatment-multiple-sclerosis-patients-now-available-hackensack-meridian-health-hackensack-university-medical-center/
Progressive Multiple Sclerosis (MS) - Medical Need
Multiple sclerosis is a condition characterized by areas of damage (lesions) on the brain and spinal cord. These lesions are associated with destruction of the covering that protects nerves and promotes the efficient transmission of nerve impulses (the myelin sheath) and damage to nerve cells. Multiple sclerosis is considered an autoimmune disorder; autoimmune disorders occur when the immune system malfunctions and attacks the bodys own tissues and organs, in this case tissues of the nervous system.. Multiple sclerosis usually begins in early adulthood, between ages 20 and 40. The symptoms vary widely, and affected individuals can experience one or more effects of nervous system damage. Multiple sclerosis often causes sensory disturbances in the limbs, including a prickling or tingling sensation (paresthesia), numbness, pain, and itching. Some people experience Lhermitte sign, which is an electrical shock-like sensation that runs down the back and into the limbs. This sensation usually occurs ...
http://medicalneed.com/healthcare-professionals/progressive-multiple-sclerosis/
Research Paper on Multiple Sclerosis | CustomWritings.com BlogResearch Paper on Multiple Sclerosis | CustomWritings.com Blog
Introduction Multiple Sclerosis is a demyelization disorder of the central nervous system and the spinal cord; which leads to patches of plaques in the regions of the brain and spinal cord. (Stedmans Medical Dictionary, 2000) There are many types of multiple sclerosis, however the severity and type of multiple
https://www.customwritings.com/blog/sample-research-papers/research-paper-multiple-sclerosis.html
Modifying effects of HLA-DRB1 allele interactions on age at onset of multiple sclerosis in Western Australia - Murdoch...Modifying effects of HLA-DRB1 allele interactions on age at onset of multiple sclerosis in Western Australia - Murdoch...
The contribution of genetic factors to the age at onset in multiple sclerosis is poorly understood. Our objective was to investigate the disease modifying effects of HLA-DRB1 alleles and allele interactions on age at onset of multiple sclerosis. High-resolution four-digit HLA-DRB1 genotyping was performed in a cohort of 461 multiple sclerosis patients from the Perth Demyelinating Diseases Database. Carriage of the HLA-DRB1*1501 risk allele was not significantly associated with age at onset but HLA-DRB1*0801 was associated with a later onset of the disease. The HLA-DRB1*0401 allele was associated with a reduced age at onset when combined with DRB1*1501 but may delay age at onset when combined with DRB1*0801. These findings indicate that epistatic interactions at the HLA-DRB1 locus have significant modifying effects on age at onset of multiple sclerosis and demonstrate the value of high-resolution genotyping in detecting such associations.. ...
http://researchrepository.murdoch.edu.au/id/eprint/6456/
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active...Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active...
Delaying disability progression is a critical goal of MS treatment, and historically, patients with advancing disease have had very few options to help them, said Fabrice Chouraqui, President, Novartis Pharmaceuticals Corporation. Weve had a longstanding mission to enhance the understanding of MS and help reimagine treatment options, and were excited to expand on our legacy with Mayzent for patients with relapsing forms of MS, including SPMS with active disease.. Most patients transition from RRMS to SPMS over time1. Therefore, starting therapy early is critical for patients to help slow the rate of disability progression. Disability progression most frequently includes - but is not limited to - an impact on ambulation, which could lead to patients needing a walking aid or a wheelchair5.. We are grateful that there is a new treatment option for adults with active secondary progressive MS, said Bruce Bebo, PhD, Executive Vice President, Research, National MS Society. We are hopeful this ...
https://www.novartis.us/news/media-releases/novartis-receives-fda-approval-mayzent-siponimod-first-oral-drug-treat-secondary
chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months : IBZ Onlinechronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months : IBZ Online
General note: By using the comment function on degruyter.com you agree to our Privacy Statement. A respectful treatment of one another is important to us. Therefore we would like to draw your attention to our House Rules ...
https://www.degruyter.com/view/IBZ/ID361965631?rskey=gCgjFN&result=78
MS Views and News:: Data from Genzymes Multiple Sclerosis Franchise Featured at AAN
of Myelin and Maintenance of Axonal Conduction in the MOG-induced EAE Mouse Model (Poster Session I -- P1.220; April 28; 3:00 p.m. EDT) -- Anti-murine CD52 Antibody Treatment Does Not Adversely Affect the Migratory Ability of Immune Cells (Poster Session I -- P1.222; April 28; 3:00 p.m. EDT) -- Successful Detection and Management of Immune Thrombocytopenia in Alemtuzumab-Treated Patients with Active Relapsing-Remitting Multiple Sclerosis (Poster Session II -- P2.198; April 29; 7:30 a.m. EDT) -- Thyroid Autoimmune Adverse Events in Patients Treated with Alemtuzumab for Relapsing-remitting Multiple Sclerosis: Four-year Follow-up of the CARE-MS Studies (Poster Session II -- P2.199; April 29; 7:30 a.m. EDT) -- Safety of Using Disease-modifying Therapy Post-alemtuzumab Treatment in Patients With Relapsing-remitting Multiple Sclerosis in the Core and Extension Phases of CAMMS223, CARE-MS I, and CARE-MS II Studies (Poster Session II -- P2.201; April 29; 7:30 a.m. EDT) -- Alemtuzumab Has Similar ...
http://wwwmsviewsandrelatednews.blogspot.com/2014/04/data-from-genzymes-multiple-sclerosis.html
Characterizing Inflammatory and Neurodegenerative Pathways Driving Clinical Disease in Primary Progressive Multiple Sclerosis -...Characterizing Inflammatory and Neurodegenerative Pathways Driving Clinical Disease in Primary Progressive Multiple Sclerosis -...
Background: To develop more effective treatments for multiple sclerosis (MS), researchers require a better understanding of the biological processes that lead to susceptibility and progression, as well as animal models that emulate human disease. Unlike relapsing-remitting MS, progressive MS is not managed with current therapies, and the development of effective treatments is hindered due to the lack of animal models that resemble human disease.. Overview: To address this gap, this team of researchers developed the first mouse model of MS based on a human mutation (Nr1h3 gene) to understand the mechanisms involved in disease progression. The Nr1h3 gene mutation is known to cause severe and rapidly progressive MS in families. Preliminary analysis of this model has already revealed parallels with the human disease. Dr. Jacqueline Quandt and team will conduct a comprehensive characterization of this new animal model to identify the underlying biological pathways and mechanisms responsible for the ...
https://mssociety.ca/about-ms-research/about-our-research-program/research-we-fund/99/characterizing-inflammatory-and-neurodegenerative-pathways-driving-clinical-disease-in-primary-progressive-multiple-sclerosis
Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS | Business WireBiogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS | Business Wire
The Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis (SPMS) did not achieve its primary and secondary endpoints, Biogen (NASDAQ: BIIB) reported today. During the study, natalizumab was generally well tolerated and adverse events were consistent with its known safety profile. ASCEND evaluated the efficacy and safety of natalizumab to slow the accumulation of disability progression unrelated to relapse in SPMS patients, an unmet medical need. The majority of study participants had EDSS scores of 6.0 to 6.5 (walking aid required) and were non-relapsing for two years prior to enrollment in the study. The studys composite primary endpoint evaluated the percentage of patients whose disability had progressed on one or more of three disability measurements comprising the composite endpoint. Natalizumab demonstrated a
https://www.ntbinfo.no/pressemelding/biogen-reports-top-line-results-from-phase-3-study-evaluating-natalizumab-in-secondary-progressive-ms?publisherId=90063&releaseId=8312249
Two new studies support the link between the gut microbiome and multiple sclerosis | The Translational Microbiome Research...Two new studies support the link between the gut microbiome and multiple sclerosis | The Translational Microbiome Research...
Previous research has found that multiple sclerosis (MS) patients may have a specific microbial signature in their gut microbiota that could impact disease pathogenesis. However, it is not known to what extent structural and functional changes in the gut microbiota are primary contributors to MS pathogenesis and which underlying mechanisms are involved.. A new study, led by Dr. Sergio Baranzini from the Department of Neurology at the University of California San Francisco (USA), has found that specific gut bacteria from multiple sclerosis patients regulate immune responses and exacerbate MS-like symptoms in mice.. The researchers used 16S ribosomal ribonucleic acid (rRNA) gene sequencing of stool samples from 71 untreated relapsing-remitting MS patients and 71 healthy controls.. Although they did not find shifts in the gut microbiota structure, specific bacterial taxa were significantly associated with MS. Both Akkermansia muciniphila and Acinetobacter calcoaceticus were increased in MS ...
http://www.translationalmicrobiome.org/news/two-new-studies-support-the-link-between-the-gut-microbiome-and-multiple-sclerosis/
Nationwide Incidence of Acquired Central Nervous System Demyelination in Icelandic Children.
Eighteen patients with acquired demyelinating syndromes and multiple sclerosis were included, the total annual incidence being 1.15/100,000 (acquired demyelinating syndromes 1.02 and multiple sclerosis 0.45/100,000). The median age at diagnosis was 14.25 years (range 1.25-17.5 years). Thirteen patients were initially diagnosed with clinically isolated syndrome, two had acute disseminated encephalomyelitis, two had multiple sclerosis, and one had neuromyelitis optica. Seven children were diagnosed with multiple sclerosis; three patients with clinically isolated syndrome developed multiple sclerosis after the age of 18 and were not included in the multiple sclerosis group. The gender ratio was equal. Of the nine girls, seven were diagnosed with clinically isolated syndrome. Most patients (11 of 18) were diagnosed during the period January through March. Oligoclonal bands in cerebrospinal fluid were exclusively found in patients with multiple sclerosis and clinically isolated syndrome and 13 of 14 ...
https://www.hirsla.lsh.is/handle/2336/605103
Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
The major intermediate cytoskeletal protein of astrocytes, glial fibrillary acidic protein (GFAP), and that of axons, neurofilament light protein (NFL), may both be released into the cerebrospinal fluid (CSF) during pathological processes in the central nervous system (CNS). We investigated GFAP and NFL levels in CSF as possible biomarkers for progression in multiple sclerosis (MS). Patients with relapsing-remitting MS (RRMS, n = 15) or secondary progressive MS (SPMS, n = 10) and healthy control subjects (n = 28) were examined twice with an interval of 8-10 years apart. Neurological deficits were scored with the Expanded Disability Status Scale (EDSS). GFAP and NFL levels were determined in CSF by enzyme-linked immunosorbent assay (ELISA). GFAP levels and NFL levels correlated with age (r and r (s) = 0.50, p = 0.006). Adjusting for age, MS patients had increased GFAP levels compared with controls (p = 0.03) and GFAP levels correlated with neurological disability (EDSS, r = 0.51, p | 0.05) and disease
http://publications.lib.chalmers.se/publication/144678-glial-fibrillary-acidic-protein-a-potential-biomarker-for-progression-in-multiple-sclerosis
The use of glatiramer acetate (Copaxone ®) in people with multiple sclerosis | CochraneThe use of glatiramer acetate (Copaxone ®) in people with multiple sclerosis | Cochrane
This is an updated Cochrane review of the previous version published (Cochrane Database of Systematic Reviews 2004 , Issue 1 . Art. No.: CD004678. DOI: 10.1002/14651858.CD004678). Treatment with glatiramer acetate (Copaxone ®) of patients with Relapsing-Remitting (RRMS) and with Progressive Multiple Sclerosis (PMS) seems to have few beneficial effects in RRMS, while the drug is not effective in PMS patients. Previous studies indicate that glatiramer acetate, a synthetic drug, is effective in animal models of MS, and shows some benefits in MS patients. The objective of this review was to assess the efficacy of glatiramer acetate in RRMS and PMS patients.. Among the pertinent medical literature six studies met the criteria of the methodological quality necessary for their inclusion in this review. 540 RRMS patients and 1049 PMS patients contributed to this analysis. The data showed no beneficial effects on disease progression in both MS forms, a slight beneficial effect in the reduction of risk ...
https://www.cochrane.org/CD004678/MS_the-use-of-glatiramer-acetate-copaxone-r-in-people-with-multiple-sclerosis
Social Security Disability Benefits for Multiple Sclerosis (Page 1) - Law FirmSocial Security Disability Benefits for Multiple Sclerosis (Page 1) - Law Firm
The cause of MS is unknown. MS is more common in temperate than tropical areas, and moving between geographic regions at certain ages can affect the risk developing the disorder. Theories as to cause have considered a virus, brain trauma, or a problem in the immune system, but these are little more than speculation. Close relatives of people with multiple sclerosis have a higher incidence of the disorder, and this supports the possibility of a genetic contribution.. Genes on multiple chromosomes are suspected of playing some role in MS. People with multiple sclerosis are more likely to have abnormalities in human leukocyte antigens (HLA), proteins coded from chromosome 6 and important in the functioning of the immune system. If there is a genetic contribution to the development of MS, the path of cause and effect is not yet understood. There is no genetic test for multiple sclerosis, and even if there is a genetic contribution to cause, unknown environmental factors (such as a particular ...
https://www.disabilitylawyerdenver.com/multiple-sclerosis/
IJMS | Free Full-Text | Glatiramer Acetate in Treatment of Multiple Sclerosis: A Toolbox of Random Co-Polymers for Targeting...IJMS | Free Full-Text | Glatiramer Acetate in Treatment of Multiple Sclerosis: A Toolbox of Random Co-Polymers for Targeting...
Multiple sclerosis is a disease of the central nervous system, resulting in the demyelination of neurons, causing mild to severe symptoms. Several anti-inflammatory treatments now play a significant role in ameliorating the disease. Glatiramer acetate (GA) is a formulation of random polypeptide copolymers for the treatment of relapsing-remitting MS by limiting the frequency of attacks. While evidence suggests the influence of GA on inflammatory responses, the targeted molecular mechanisms remain poorly understood. Here, we review the multiple pharmacological modes-of-actions of glatiramer acetate in treatment of multiple sclerosis. We discuss in particular a newly discovered interaction between the leukocyte-expressed integrin αMβ2 (also called Mac-1, complement receptor 3, or CD11b/CD18) and perspectives on the GA co-polymers as an influence on the function of the innate immune system.
http://www.mdpi.com/1422-0067/13/11/14579/notes
Setting Goals with Secondary Progressive MSSetting Goals with Secondary Progressive MS
Dan and Jennifer Digmann, authors of the book Despite MS to Spite MS, share how they set goals and prioritize what matters to them. Jennifer lives with secondary progressive MS and Dan lives with relapsing-remitting MS.
https://www.healthline.com/health/managing-ms/secondary-progressive-ms-setting-goals
Statin Associated with Slower Brain Atrophy in Progressive Multiple Sclerosis (FREE) | Liberation Treatment CCSVI
By Joe Elia A phase 2 study shows a slowing of brain atrophy with a high-dose statin in patients with secondary progressive multiple sclerosis.According to a Lancet study, 140 patients were … (Source: Physicians First Watch current issue)
http://liberationtreatmentccsvi.com/2014/03/statin-associated-with-slower-brain-atrophy-in-progressive-multiple-sclerosis-free/
Multiple sclerosisMultiple sclerosis
List of multiple sclerosis organizations List of people with multiple sclerosis Compston A, Coles A (October 2008). "Multiple ... "The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials". Multiple Sclerosis. ... these include tumefactive multiple sclerosis, Balo concentric sclerosis, Schilder's diffuse sclerosis, and Marburg multiple ... National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis". Neurology ...
https://en.wikipedia.org/wiki/Multiple_sclerosis
Malignant multiple sclerosisMalignant multiple sclerosis
Tumefactive multiple sclerosis Marburg acute multiple sclerosis Multiple sclerosis Autologous stem cell transplantation ... Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome. Multiple ... Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome. Multiple ... Malignant multiple sclerosis is used to describe MS patients who reach significant level of disability in a short period of ...
https://en.wikipedia.org/wiki/Malignant_multiple_sclerosis
Multiple Sclerosis TrustMultiple Sclerosis Trust
The Multiple Sclerosis Trust (MS Trust) is an independent, national UK charity that was established in 1993. The MS Trust works ... MS Trust website "Multiple Sclerosis Trust, registered charity no. 1088353". Charity Commission for England and Wales. (All ... "Bone marrow cell treatment for chronic multiple sclerosis". MS Trust website. Retrieved 29 November 2012. "Pilates based core ... Research currently being funded includes: University of Bristol, Bone marrow cell treatment for chronic multiple sclerosis ...
https://en.wikipedia.org/wiki/Multiple_Sclerosis_Trust
Multiple Sclerosis SocietyMultiple Sclerosis Society
... may refer to: The Multiple Sclerosis Society of Great Britain The Multiple Sclerosis Society of ... Other multiple sclerosis societies This disambiguation page lists articles associated with the title Multiple Sclerosis Society ... Canada The National Multiple Sclerosis Society of the United States. ...
https://en.wikipedia.org/wiki/Multiple_Sclerosis_Society
Multiple sclerosis researchMultiple sclerosis research
"Myelocortical multiple sclerosis: a subgroup of multiple sclerosis patients with spinal cord and cortical demyelination". ... In 1996, the US National Multiple Sclerosis Society (NMSS) Advisory Committee on Clinical Trials in Multiple Sclerosis (ACCTMS ... cardiac arrythmia "Mayo Clinic: Multiple Sclerosis". "FDA approves new oral treatment for multiple sclerosis". fda.gov. ... pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case". Multiple Sclerosis Journal. 22 (12): 1541 ...
https://en.wikipedia.org/wiki/Multiple_sclerosis_research
Multiple sclerosis biomarkersMultiple sclerosis biomarkers
Some PPMS patients have been found to have a special genetic variant named rapidly progressive multiple sclerosis In these ... Comparative Effectiveness Research (CER) is an emerging field in Multiple Sclerosis treatment. The response of the disease to ... Several biomarkers for diagnosis of multiple sclerosis, disease evolution and response to medication (current or expected) are ... specific proteins in circulating CD4+ T cells is a risk factor for conversion from CIS to clinically defined multiple sclerosis ...
https://en.wikipedia.org/wiki/Multiple_sclerosis_biomarkers
Tumefactive multiple sclerosisTumefactive multiple sclerosis
... the world suffer from multiple sclerosis Tumefactive multiple sclerosis cases make up 1 to 2 of every 1000 multiple sclerosis ... Idiopathic inflammatory demyelinating diseases Malignant multiple sclerosis Marburg acute multiple sclerosis Xia L., Lin S., ... yielding a diagnosis of Multiple Sclerosis. Hence the name "tumefactive multiple sclerosis". When the demyelinating lesion ... Tumefactive multiple sclerosis is a condition in which the central nervous system of a person has multiple demyelinating ...
https://en.wikipedia.org/wiki/Tumefactive_multiple_sclerosis
Multiple Sclerosis JournalMultiple Sclerosis Journal
The Multiple Sclerosis Journal (formerly Multiple Sclerosis) is a monthly peer-reviewed medical journal covering the clinical ... neurology of multiple sclerosis. The editor-in-chief is Alan J Thompson (University College London). It was established in 1995 ...
https://en.wikipedia.org/wiki/Multiple_Sclerosis_Journal
Multiple Sclerosis FoundationMultiple Sclerosis Foundation
MS Focus: The Multiple Sclerosis Foundation, also known as the Multiple Sclerosis Foundation or just MS Focus, is a 501(c)(3) ... Multiple Sclerosis News Today. Retrieved 30 March 2017. "Charity Report - Multiple Sclerosis Foundation - give.org". www.give. ... Multiple Sclerosis News Today. Retrieved 30 March 2017. Ferreira, Leonor Mateus (19 June 2014). "Multiple Sclerosis Foundation ... According to the Better Business Bureau, the Multiple Sclerosis Foundation did not disclose accountability information, and ...
https://en.wikipedia.org/wiki/Multiple_Sclerosis_Foundation
Multiple sclerosis diagnosisMultiple sclerosis diagnosis
National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis". Neurology ... National Multiple Sclerosis Society. "Changes in multiple sclerosis disease-course (or "type") descriptions" (PDF). Archived ( ... Atlas: Multiple Sclerosis Resources in the World, 2008. World Health Organization & Multiple Sclerosis International Federation ... February 2021). "Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome". Multiple Sclerosis. 27 (2): ...
https://en.wikipedia.org/wiki/Multiple_sclerosis_diagnosis
National Multiple Sclerosis SocietyNational Multiple Sclerosis Society
The National Multiple Sclerosis Society (NMSS) is a nonprofit organization that was founded in New York City as the Association ... "National Multiple Sclerosis Society". www.weizmann.ac.il. Retrieved 2017-05-13. "Home - Office of Sponsored Projects - The ... Lawry was a lawyer looking for a cure for her brother, Bernard, who was afflicted with multiple sclerosis when she realized ... "Our Story". National MS Society.{{cite web}}: CS1 maint: url-status (link) "National Multiple Sclerosis Society on the Forbes ...
https://en.wikipedia.org/wiki/National_Multiple_Sclerosis_Society
Multiple sclerosis functional compositeMultiple sclerosis functional composite
"The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials". Multiple Sclerosis. ... and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis". BMC Neurology. 14 (1): 58. doi: ... The Multiple Sclerosis Functional Composite (MSFC) is a clinical trial outcome measure of assessing the severity of multiple ... It was developed over two years from 1994 to 1996 by the National Multiple Sclerosis Society. MSFC was developed to improve the ...
https://en.wikipedia.org/wiki/Multiple_sclerosis_functional_composite
Management of multiple sclerosisManagement of multiple sclerosis
"Multiple sclerosis: its effects on you and those you love" (PDF). Multiple Sclerosis Society of Canada. 2008. Retrieved 11 May ... Neild C (2009). Women's Health and Multiple Sclerosis (PDF). ISBN 978-0-921323-99-0. Multiple Sclerosis Society of Great ... Bakshi R (June 2003). "Fatigue associated with multiple sclerosis: diagnosis, impact and management". Multiple Sclerosis. 9 (3 ... October 2006). "Cannabis use in patients with multiple sclerosis". Multiple Sclerosis. 12 (5): 646-51. doi:10.1177/ ...
https://en.wikipedia.org/wiki/Management_of_multiple_sclerosis
Pathophysiology of multiple sclerosisPathophysiology of multiple sclerosis
"Exploring the overlap between multiple sclerosis, tumefactive demyelination and Baló's concentric sclerosis". Multiple ... Multiple sclerosis can be pathologically defined as the presence of distributed glial scars (or sclerosis) in the central ... The lesion project page MRI and CT of Multiple Sclerosis MedPix Image Database (CS1 maint: multiple names: authors list, All ... Multiple sclerosis borderline Golan, Daniel; Staun-Ram, Elsebeth; Miller, Ariel (2016). "Shifting paradigms in multiple ...
https://en.wikipedia.org/wiki/Pathophysiology_of_multiple_sclerosis
Multiple Sclerosis International FederationMultiple Sclerosis International Federation
The Multiple Sclerosis International Federation (MSIF) was established in 1967 as an international body linking the activities ... Since May 2009, MSIF has organized a World Multiple Sclerosis Day, which is now supported by MS organizations and individuals ... and to speak out globally on behalf of those affected by multiple sclerosis.[citation needed] MSIF works to achieve its goal ... Multiple sclerosis organizations, Organisations based in the London Borough of Southwark, Organizations established in 1967). ...
https://en.wikipedia.org/wiki/Multiple_Sclerosis_International_Federation
Multiple sclerosis drug pipelineMultiple sclerosis drug pipeline
Saida T (Nov 2004). "Multiple sclerosis: treatment and prevention of relapses and progression in multiple sclerosis". Rinsho ... Vukusic S, Confavreux C (March 2006). "[Multiple sclerosis and pregnancy]" [Multiple sclerosis and pregnancy]. Revue ... Multiple Sclerosis News Today". 23 March 2016. Clinical trial number NCT00067327 for "Treatment of Multiple Sclerosis Using ... remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial". Multiple Sclerosis. ...
https://en.wikipedia.org/wiki/Multiple_sclerosis_drug_pipeline
Marburg acute multiple sclerosisMarburg acute multiple sclerosis
... , also known as Marburg multiple sclerosis or acute fulminant multiple sclerosis, is considered ... Malignant multiple sclerosis Tumefactive multiple sclerosis Fontaine, B. (2001). "Les formes frontières de sclérose en plaques ... "Marburg type and Balò's concentric sclerosis: rare and acute variants of multiple sclerosis". Neurol. Sci. 25 (Suppl): S361-3. ... "Autologous stem-cell transplantation in malignant multiple sclerosis: A case with a favorable long-term outcome". Multiple ...
https://en.wikipedia.org/wiki/Marburg_acute_multiple_sclerosis
Multiple Sclerosis Discovery ForumMultiple Sclerosis Discovery Forum
... (MSDF) is a non-profit online resource created to speed progress toward a cure for multiple ... MSDF is a joint activity of Accelerated Cure Project for Multiple Sclerosis (ACP) and the MassGeneral Institute for ... 2012) Web Forum Set to Tackle Multiple Sclerosis; AlzForum. Das, Sudeshna; McCaffrey, Patricia G.; Talkington, Megan W. T.; ... Schizophrenia Research Forum Pain Research Forum (Multiple sclerosis, Internet properties established in 2012, American medical ...
https://en.wikipedia.org/wiki/Multiple_Sclerosis_Discovery_Forum
Pathology of multiple sclerosisPathology of multiple sclerosis
Cause of nerve fiber damage in multiple sclerosis identified Wolswijk G (15 January 1998). "Chronic stage multiple sclerosis ... secondary progressive multiple sclerosis) than in RRMS (relapsing-remitting multiple sclerosis) and most of them remain ... Multiple Sclerosis Lesion Type Dictates Effective Treatment Bitsch A, Brück W (2002). "Differentiation of multiple sclerosis ... "Spinal cord grey matter lesions in multiple sclerosis detected by post-mortem high field MR imaging". Multiple Sclerosis. 15 (2 ...
https://en.wikipedia.org/wiki/Pathology_of_multiple_sclerosis
Multiple sclerosis signs and symptomsMultiple sclerosis signs and symptoms
"Olfactory dysfunction in multiple sclerosis". Multiple Sclerosis and Related Disorders. 21: 92-96. doi:10.1016/j.msard.2018.02. ... Probable multiple sclerosis patients, meaning after a first attack but before a secondary confirmatory one, have up to 50 ... Multiple sclerosis can cause a variety of symptoms: changes in sensation (hypoesthesia), muscle weakness, abnormal muscle ... Pucci E, Branãs P, D'Amico R, Giuliani G, Solari A, Taus C (2007). Pucci E (ed.). "Amantadine for fatigue in multiple sclerosis ...
https://en.wikipedia.org/wiki/Multiple_sclerosis_signs_and_symptoms
List of multiple sclerosis organizationsList of multiple sclerosis organizations
Multiple Sclerosis Society of Great Britain Multiple Sclerosis Trust Multiple Sclerosis Society of Canada Fly for MS Multiple ... List of multiple sclerosis organizations in different countries around the world. Multiple Sclerosis International Federation ... Sclerosis Foundation Myelin Repair Foundation National Multiple Sclerosis Society (Articles with short description, Short ... description is different from Wikidata, Dynamic lists, Lists of medical and health organizations, Multiple sclerosis ...
https://en.wikipedia.org/wiki/List_of_multiple_sclerosis_organizations
Multiple Sclerosis Society of CanadaMultiple Sclerosis Society of Canada
Founded in 1948, the Multiple Sclerosis Society of Canada promotes multiple sclerosis (MS) research and provides education and ... Multiple sclerosis organizations, Medical and health organizations based in Ontario). ...
https://en.wikipedia.org/wiki/Multiple_Sclerosis_Society_of_Canada
Multiple Sclerosis Society of Great BritainMultiple Sclerosis Society of Great Britain
The Multiple Sclerosis Society (MS Society) is the UK's largest charity for people affected by multiple sclerosis (MS). Based ... The MS Society is the UK's largest charity for people affected by multiple sclerosis (MS). It is a membership organisation, ... Multiple Sclerosis Society UK". www.mssociety.org.uk. Retrieved 2016-10-24. Official site (Pages using infobox organization ... Multiple sclerosis organizations, Organisations based in the London Borough of Barnet, Organizations established in 1953, 1953 ...
https://en.wikipedia.org/wiki/Multiple_Sclerosis_Society_of_Great_Britain
List of people with multiple sclerosisList of people with multiple sclerosis
... refusing to let multiple sclerosis halt cricket career Pockrass, Bob. "Trevor Bayne diagnosed with multiple sclerosis; cleared ... "Multiple Sclerosis Research: Malu Dreyer - MS Champion". 1 October 2012. Edwards, Donna (7 July 2017). "To my colleagues in ... "Victoria Williams Has Multiple Sclerosis". msstrength. 28 January 2009. "Mavericks G Wright joins team while battling MS". ESPN ... This is a list of notable people with multiple sclerosis, a demyelinating disease in which the insulating covers of nerve cells ...
https://en.wikipedia.org/wiki/List_of_people_with_multiple_sclerosis
Patient Reported Outcome Indices for Multiple SclerosisPatient Reported Outcome Indices for Multiple Sclerosis
... in multiple sclerosis patients in Germany (PANGAEA)". Multiple Sclerosis. 18 (4): 222. doi:10.1177/1352458512459019. S2CID ... Multiple Sclerosis. 19 (5): 631-638. doi:10.1177/1352458512463481. PMID 23069874. S2CID 6838286. (Multiple sclerosis, Quality ... "The development of patient-reported outcome indices for multiple sclerosis (PRIMUS)". Multiple Sclerosis Journal. 15 (9): 1092- ... The Patient Reported Outcome Indices for Multiple Sclerosis (PRIMUS) is a disease specific patient-reported outcome ...
https://en.wikipedia.org/wiki/Patient_Reported_Outcome_Indices_for_Multiple_Sclerosis
Corinne Goldsmith Dickinson Center for Multiple SclerosisCorinne Goldsmith Dickinson Center for Multiple Sclerosis
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis is a multiple sclerosis research and treatment center in New York ... The laboratory is currently supported by grants from the National Institutes of Health, the National Multiple Sclerosis Society ... The pathologic hallmarks of multiple sclerosis are central inflammation, blood-brain barrier permeability, demyelination, ... Jiwa Frontier in Multiple Sclerosis: New and Emerging Therapies, by Bruce A. Cohen, et al. Coordinates: 40°47′21″N 73°57′17″W ...
https://en.wikipedia.org/wiki/Corinne_Goldsmith_Dickinson_Center_for_Multiple_Sclerosis
National Multiple Sclerosis Society, National Capital ChapterNational Multiple Sclerosis Society, National Capital Chapter
... is a local chapter of the National Multiple Sclerosis Society. ... "Employment". National Multiple Sclerosis Society. Retrieved 2019-08-31. "About the Society". National Multiple Sclerosis ... National Multiple Sclerosis Society. Retrieved 2019-08-31. "Resources & Support". National Multiple Sclerosis Society. ... "Advocate for Change". National Multiple Sclerosis Society. 2012-03-06. Retrieved 2019-08-31. (Orphaned articles from December ...
https://en.wikipedia.org/wiki/National_Multiple_Sclerosis_Society,_National_Capital_Chapter
Diffuse myelinoclastic sclerosisDiffuse myelinoclastic sclerosis
Balo concentric sclerosis and Marburg multiple sclerosis. Symptoms are similar to those in multiple sclerosis and may include ... Myelinoclastic diffuse sclerosis (Schilder's disease) is immunologically distinct from multiple sclerosis: results from ... This disease is considered one of the borderline forms of multiple sclerosis because some authors consider them different ... Fontaine B (2001). "[Borderline forms of multiple sclerosis]". Rev. Neurol. (Paris) (in French). 157 (8-9 Pt 2): 929-34. PMID ...
https://en.wikipedia.org/wiki/Diffuse_myelinoclastic_sclerosis
Sclerosis (medicine)Sclerosis (medicine)
Multiple sclerosis, or focal sclerosis, is a central nervous system disease which affects coordination. Osteosclerosis, a ... Tuberous sclerosis, a rare genetic disease which affects multiple systems. "Welcome To The NephCure Foundation". Archived from ... Common medical conditions whose pathology involves sclerosis include: Amyotrophic lateral sclerosis-also known as Lou Gehrig's ... Sclerosis (from Greek σκληρός sklērós, "hard") is the stiffening of a tissue or anatomical feature, usually caused by a ...
https://en.wikipedia.org/wiki/Sclerosis_(medicine)
Tuberous sclerosisTuberous sclerosis
... complex affects multiple organ systems so a multidisciplinary team of medical professionals is required.[ ... Tuberous sclerosis complex is diagnosed with clinical and genetic tests. There are many different mutations in the TSC1 and ... Tuberous sclerosis complex (TSC) is a rare multisystem autosomal dominant genetic disease that causes non-cancerous tumours to ... The disease is often abbreviated to tuberous sclerosis, which refers to the hard swellings in the brains of patients, first ...
https://en.wikipedia.org/wiki/Tuberous_sclerosis
Deaths in December 2014Deaths in December 2014
Chen Shi-chang, 80, Taiwanese politician, multiple organ failure. Dave Comer, 58, New Zealand film location scout (The Lord of ... Rocky Wood, 55, New Zealand-born Australian author, amyotrophic lateral sclerosis. Don L. Anderson, 81, American geophysicist, ... Deborah Bone, 51, English mental health nurse, inspired Disco 2000, multiple myeloma. Antonio Brack Egg, 74, Peruvian ecologist ... Juanito Remulla, Sr., 81, Filipino politician, Governor of Cavite (1979-1986), multiple organ failure. Sir Ivor Richardson, 84 ...
https://en.wikipedia.org/wiki/Deaths_in_December_2014
Czech Republic at the 2016 Summer ParalympicsCzech Republic at the 2016 Summer Paralympics
... for example dwarfism or multiple sclerosis. Each Paralympic sport then has its own classifications, dependent upon the specific ...
https://en.wikipedia.org/wiki/Czech_Republic_at_the_2016_Summer_Paralympics
David LanderDavid Lander
Lander had multiple sclerosis. Diagnosed on May 15, 1984, at Cedars-Sinai Medical Center, he went public in 1999 and regularly ... He also served as a Goodwill ambassador for the National Multiple Sclerosis Society. David Leonard Landau was born in Brooklyn ... Lander died of complications from Multiple sclerosis at Cedars-Sinai Medical Center in Los Angeles, California, on December 4, ... In 2002, his autobiography was published, titled Fall Down Laughing: How Squiggy Caught Multiple Sclerosis and Didn't Tell ...
https://en.wikipedia.org/wiki/David_Lander
Armenia at the 2016 Summer ParalympicsArmenia at the 2016 Summer Paralympics
... for example dwarfism or multiple sclerosis. Each Paralympic sport then has its own classifications, dependent upon the specific ...
https://en.wikipedia.org/wiki/Armenia_at_the_2016_Summer_Paralympics
Kyrgyzstan at the 2016 Summer ParalympicsKyrgyzstan at the 2016 Summer Paralympics
... for example dwarfism or multiple sclerosis. Each Paralympic sport then has its own classifications, dependent upon the specific ...
https://en.wikipedia.org/wiki/Kyrgyzstan_at_the_2016_Summer_Paralympics
Alia TabbaaAlia Tabbaa
She is also the president of the Multiple Sclerosis Foundation, and as of 2006 became the president of the Cerebral Palsy ...
https://en.wikipedia.org/wiki/Alia_Tabbaa
NeurorehabilitationNeurorehabilitation
Thompson, AJ (June 2005). "Neurorehabilitation in multiple sclerosis: foundations, facts and fiction". Current Opinion in ... Rosti-Otajärvi, Eija M.; Hämäläinen, Päivi I. (2014-02-11). "Neuropsychological rehabilitation for multiple sclerosis". The ... Cord Injury Cerebral palsy Parkinson's disease Brain injury Anoxic brain injury Traumatic brain injury Multiple sclerosis Post- ...
https://en.wikipedia.org/wiki/Neurorehabilitation
Susacs syndromeSusac's syndrome
Multiple sclerosis (MS) and acute disseminated encephalomyelitis (ADEM) can mimic the MRI changes seen in patients with Susac's ... A concern about this illness is that it mimics multiple sclerosis when looking at the vision loss and brain lesions. If close ... The first patient underwent brain biopsy, which revealed sclerosis of the media and adventitia of small pial and cortical ...
https://en.wikipedia.org/wiki/Susac's_syndrome
Personal Independence PaymentPersonal Independence Payment
The Multiple Sclerosis Society of Great Britain produced a report about its members experiences of the test in September 2015. ... Almost half multiple sclerosis patients claiming PIP must be reassessed inside two years, the MS Society claims. "We're ... In 2017 Member of Parliament Carol Monaghan said she would challenge four cases of patients with multiple sclerosis being ... multiple sclerosis, and motor neurone disease are made to attend reassessments though it is unlikely they will get better and ...
https://en.wikipedia.org/wiki/Personal_Independence_Payment
Rehabilitation psychologyRehabilitation psychology
... multiple sclerosis, mild cognitive impairment, ADHD, and a variety of other medical conditions that affect cognitive ... AIDS Acquired brain injury Cancer Chronic pain Concussion Limb loss Multiple sclerosis Neuromuscular disorders Spinal cord ... CS1 maint: multiple names: authors list, Articles with short description, Short description is different from Wikidata, ... OCLC 9575320.{{cite book}}: CS1 maint: multiple names: authors list (link) Wright, Beatrice A. (1972). "Value-laden beliefs and ...
https://en.wikipedia.org/wiki/Rehabilitation_psychology
T-cell vaccinationT-cell vaccination
Research on T-cell vaccination so far has focused mostly on multiple sclerosis and to a lesser extent on rheumatoid arthritis, ... Hellings N, Raus J, Stinissen P (2004). "T-cell vaccination in multiple sclerosis: update on clinical application and mode of ... Zhang J (2002). "T-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience in multiple sclerosis ...
https://en.wikipedia.org/wiki/T-cell_vaccination
Myelin-associated glycoproteinMyelin-associated glycoprotein
Mutations to the MAG gene are implicated in demyelination diseases such as multiple sclerosis. Axons in the central nervous ...
https://en.wikipedia.org/wiki/Myelin-associated_glycoprotein
Brazil at the 1972 Summer ParalympicsBrazil at the 1972 Summer Paralympics
... for example dwarfism or multiple sclerosis. Each Paralympic sport then has its own classifications, dependent upon the specific ...
https://en.wikipedia.org/wiki/Brazil_at_the_1972_Summer_Paralympics
Russia at the 2016 Summer ParalympicsRussia at the 2016 Summer Paralympics
... for example dwarfism or multiple sclerosis. Each Paralympic sport then has its own classifications, dependent upon the specific ...
https://en.wikipedia.org/wiki/Russia_at_the_2016_Summer_Paralympics
InterferonInterferon
... relapsing-remitting multiple sclerosis and slowing disease progression and activity in secondary progressive multiple sclerosis ... Overall, IFN-α can be used to treat hepatitis B and C infections, while IFN-β can be used to treat multiple sclerosis. ... Interferon beta-1a and interferon beta-1b are used to treat and control multiple sclerosis, an autoimmune disorder. This ... "Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis". Biologics: Targets and Therapy. 3: ...
https://en.wikipedia.org/wiki/Interferon
Otelia Shields HowardOtelia Shields Howard
... died in 1945, in Petersburg, from complications related to multiple sclerosis. A special "In Memoriam" ... Deaths from multiple sclerosis, 20th-century African-American people, 20th-century African-American women). ...
https://en.wikipedia.org/wiki/Otelia_Shields_Howard
And in the End...And in the End...
Marjorie Manning (Beverly Polcyn), a previous elderly multiple sclerosis patient suffering sepsis and pulmonary edema, comes in ...
https://en.wikipedia.org/wiki/And_in_the_End...
Helen Clark (British politician)Helen Clark (British politician)
Since 2005 she has worked as Head of Policy & Campaigns for the Multiple Sclerosis Society; Interim Climate Change Advisor for ...
https://en.wikipedia.org/wiki/Helen_Clark_(British_politician)
Sweden at the 2016 Summer ParalympicsSweden at the 2016 Summer Paralympics
... for example dwarfism or multiple sclerosis. Each Paralympic sport then has its own classifications, dependent upon the specific ...
https://en.wikipedia.org/wiki/Sweden_at_the_2016_Summer_Paralympics
CADASILCADASIL
Fisher, Christopher (14 March 2011). "CADASIL, A Vascular Brain Disorder, Is Often Misdiagnosed As Multiple Sclerosis". BMED ... MRIs show hypointensities on T1-weighted images and hyperintensities on T2-weighted images, usually multiple confluent white ...
https://en.wikipedia.org/wiki/CADASIL
Jim Conway (musician)Jim Conway (musician)
Conway was diagnosed with multiple sclerosis in 1983 and as a result has been reliant on a wheelchair for a number of years. At ... People with multiple sclerosis, Jazz harmonica players, Country harmonica players). ...
https://en.wikipedia.org/wiki/Jim_Conway_(musician)
PemolinePemoline
... has been studied in and reported to be effective in the treatment of fatigue due to multiple sclerosis and HIV-related ...
https://en.wikipedia.org/wiki/Pemoline
Brazil at the 2016 Summer ParalympicsBrazil at the 2016 Summer Paralympics
... for example dwarfism or multiple sclerosis. Each Paralympic sport then has its own classifications, dependent upon the specific ...
https://en.wikipedia.org/wiki/Brazil_at_the_2016_Summer_Paralympics
Sodium-potassium pumpSodium-potassium pump
"Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions". Annals of Neurology. 63 (4): 428- ...
https://en.wikipedia.org/wiki/Sodium–potassium_pump
Mitochondrial DNAMitochondrial DNA
Autosomal cells only have two copies of nuclear DNA, but can have hundreds of copies of mtDNA due to the multiple mitochondria ... In persons with amyotrophic lateral sclerosis (ALS), the enzymes that normally repair 8-oxoG DNA damages in the mtDNA of spinal ... This mechanism is not present in the nucleus and is enabled by multiple copies of mtDNA present in mitochondria. The outcome of ... PMID 28721182.{{cite journal}}: CS1 maint: multiple names: authors list (link) Barshad G, Marom S, Cohen T, Mishmar D (2018). " ...
https://en.wikipedia.org/wiki/Mitochondrial_DNA
Anne HoltsmarkAnne Holtsmark
She had to retire in 1960 because of multiple sclerosis, which confined her to a wheelchair from the 1950s onwards. She died in ... People with multiple sclerosis, Norwegian women academics, Norwegian women writers, 20th-century Norwegian translators, 20th- ...
https://en.wikipedia.org/wiki/Anne_Holtsmark
Sweden at the 1972 Summer ParalympicsSweden at the 1972 Summer Paralympics
... for example dwarfism or multiple sclerosis. Each Paralympic sport then has its own classifications, dependent upon the specific ...
https://en.wikipedia.org/wiki/Sweden_at_the_1972_Summer_Paralympics
List of diseases (C)List of diseases (C)
... subacute Cerebellar hypoplasia Cerebellar hypoplasia endosteal sclerosis Cerebellar hypoplasia tapetoretinal degeneration ... Congenital craniosynostosis maternal hyperthyroiditis Congenital cystic adenomatoid malformation Congenital cystic eye multiple ...
https://en.wikipedia.org/wiki/List_of_diseases_(C)
Sue RandallSue Randall
... multiple sclerosis, blindness, and poor childhood education. In October 1984, at age 49, Randall died of lung cancer at ... Pages using infobox person with multiple spouses, Articles with hCards, All articles with unsourced statements, Articles with ...
https://en.wikipedia.org/wiki/Sue_Randall
MurugeshpalyaMurugeshpalya
... in association with Multiple Sclerosis Society of India, holds bike rally to increase awareness on Multiple Sclerosis". "RVM ...
https://en.wikipedia.org/wiki/Murugeshpalya
Multiple sclerosis - Symptoms and causes - Mayo ClinicMultiple sclerosis - Symptoms and causes - Mayo Clinic
Multiple sclerosis Open pop-up dialog box Close Multiple sclerosis. Multiple sclerosis. In multiple sclerosis, the protective ... The resulting damage leaves lesions or scars, and this is where the name comes from: multiple sclerosis, multiple scars. Now ... What is multiple sclerosis? National Multiple Sclerosis Society. https://www.nationalmssociety.org/What-is-MS. Accessed Dec. 14 ... a neurologist specializing in multiple sclerosis at Mayo Clinic. In this video, well be covering the basics of multiple ...
https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/symptoms-causes/syc-20350269
Multiple Sclerosis Differential DiagnosesMultiple Sclerosis Differential Diagnoses
Multiple sclerosis (MS) is an immune-mediated inflammatory disease that attacks myelinated axons in the central nervous system ... National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology ... Guideline] Multiple Sclerosis Coalition. The Use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current ... encoded search term (Multiple Sclerosis) and Multiple Sclerosis What to Read Next on Medscape ...
https://www.medscape.com/answers/1146199-5772/how-is-radiation-myelitis-distinguished-from-multiple-sclerosis-ms
Multiple sclerosis: MedlinePlus GeneticsMultiple sclerosis: MedlinePlus Genetics
Multiple sclerosis is a condition characterized by areas of damage (lesions) on the brain and spinal cord . Explore symptoms, ... medlineplus.gov/genetics/condition/multiple-sclerosis/ Multiple sclerosis. ... Although the cause of multiple sclerosis is unknown, variations in dozens of genes are thought to be involved in multiple ... Multiple sclerosis is a condition characterized by areas of damage (lesions) on the brain and spinal cord. . These lesions are ...
https://medlineplus.gov/genetics/condition/multiple-sclerosis/
NIOSH - NOMS - PMRs for Multiple SclerosisNIOSH - NOMS - PMRs for Multiple Sclerosis
Multiple Sclerosis NOMS PMRs for All Trade Sector. Data from 1999, 2003-2004, 2007-2010. Suggested Citation : NIOSH (2015). ...
https://www.cdc.gov/niosh/topics/noms/noms2charts/all_trade/icd-38.html
5 Multiple Sclerosis Symptoms You Should Know5 Multiple Sclerosis Symptoms You Should Know
... and what to do if you think you have Multiple Sclerosis. ... 5 Multiple Sclerosis Symptoms You Should Know. By Rebecca ... "Multiple sclerosis is a chronic inflammatory disease of the central nervous system (brain and spinal cord)," explains Roumen ... Almost 200 people are diagnosed with multiple sclerosis (MS) every week. They join the 400,000 people in the United States and ... according to the National Multiple Sclerosis Society. You might also have tingling or numbness, perhaps along with chronic ...
https://www.prevention.com/health/g20496136/spot-multiple-sclerosis/
Neurofilaments as biomarkers in multiple sclerosisNeurofilaments as biomarkers in multiple sclerosis
Neurodegeneration is the correlate of disease progression in multiple sclerosis (MS) and thus biological biomarkers that ... Neurofilaments as biomarkers in multiple sclerosis Mult Scler. 2012 May;18(5):552-6. doi: 10.1177/1352458512443092. Epub 2012 ... Neurodegeneration is the correlate of disease progression in multiple sclerosis (MS) and thus biological biomarkers that ...
https://pubmed.ncbi.nlm.nih.gov/22492131/
Multiple sclerosis: a two-stage disease | Nature ImmunologyMultiple sclerosis: a two-stage disease | Nature Immunology
The pathogenesis of multiple sclerosis consists of an inflammatory and neurodegnerative phase. Better understanding of these ... Identification of hsa-miR-106a-5p as an impact agent on promotion of multiple sclerosis using multi-step data analysis *Samira ... Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years *Irene ... Multiple sclerosis (MS) usually begins in early adulthood with an autoimmune inflammatory "strike" against components of the ...
https://www.nature.com/articles/ni0901-762?error=cookies_not_supported&code=d2075150-b869-44be-930d-783c8a423464
Blood cell disguise halts multiple sclerosis | New ScientistBlood cell disguise halts multiple sclerosis | New Scientist
A clever disguise is all it takes to bring a halt to multiple sclerosis in mice. ... Blood cell disguise halts multiple sclerosis. Earth 20 November 2012 By Will Ferguson ...
https://www.newscientist.com/article/dn22513-blood-cell-disguise-halts-multiple-sclerosis/
This Is MS Multiple Sclerosis Knowledge & Support Community - SearchThis Is MS Multiple Sclerosis Knowledge & Support Community - Search
This Is MS Multiple Sclerosis Knowledge & Support Community. Welcome to This is MS, the leading forum for Multiple Sclerosis ...
https://www.thisisms.com/forum/search.php
Over 75 Groups Urge Congress To Immediately Pass Drug Price Reforms In Inflation Reduction Act | National Multiple Sclerosis...Over 75 Groups Urge Congress To Immediately Pass Drug Price Reforms In Inflation Reduction Act | National Multiple Sclerosis...
About Multiple Sclerosis. Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. ... d Multiple Sclerosis and COVID-19 * d COVID-19 Vaccine Guidance for People Living with MS * Timing MS Medications with COVID-19 ... 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is ...
https://www.nationalmssociety.org/About-the-Society/News/Over-75-Groups-Urge-Congress-To-Immediately-Pass-D
Relapsing Multiple Sclerosis Patients Can Look to Second Oral Agent - Managedcaremag.comRelapsing Multiple Sclerosis Patients Can Look to Second Oral Agent - Managedcaremag.com
Relapsing Multiple Sclerosis Patients Can Look to Second Oral Agent. May 4, 2021. by Paul Lendner ... Multiple sclerosis, a debilitating immune disorder that affects the brain and spinal cord, was probably first described around ... is a pyrimi-dine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis. ...
https://www.managedcaremag.com/archives/1302/1302.biotech.html
Multiple sclerosis and anesthesia: Are there risks?Multiple sclerosis and anesthesia: Are there risks?
For most people with multiple sclerosis, anesthesia is safe and carries the same level of risk as it does for people without ... Multiple sclerosis is a chronic disease of the central nervous system - the brain and spinal cord. It affects multiple areas of ... Multiple sclerosis and systemic sclerosis are two autoimmune conditions that affect different parts of the body. Learn more ... A comparison of systemic sclerosis and multiple sclerosis. Medically reviewed by Sharon Stoll, DO, MS ...
https://www.medicalnewstoday.com/articles/multiple-sclerosis-and-anesthesia?utm_source=ReadNext
Calendar | National Multiple Sclerosis SocietyCalendar | National Multiple Sclerosis Society
d Multiple Sclerosis and COVID-19 * d COVID-19 Vaccine Guidance for People Living with MS * Timing MS Medications with COVID-19 ... 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is ...
https://www.nationalmssociety.org/Chapters/TNS/Calendar
Pediatric Multiple Sclerosis Differential DiagnosesPediatric Multiple Sclerosis Differential Diagnoses
Multiple sclerosis (MS) is primarily a disease of adults. However, MS onset in children accounts for up to 10% of all MS cases. ... International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central ... Stark W, Huppke P, Gärtner J. Paediatric multiple sclerosis: the experience of the German Centre for Multiple Sclerosis in ... encoded search term (Pediatric Multiple Sclerosis) and Pediatric Multiple Sclerosis What to Read Next on Medscape ...
https://emedicine.medscape.com/article/2091406-differential
Heat Intolerance - Multiple Sclerosis - MedHelpHeat Intolerance - Multiple Sclerosis - MedHelp
You are reading content posted in the Multiple Sclerosis Community Ask a question ...
https://medhelp.org/posts/Multiple-Sclerosis/Heat-Intolerance/show/2408724
Multiple Sclerosis (MS) Imaging LaboratoryMultiple Sclerosis (MS) Imaging Laboratory
The Multiple Sclerosis (MS) Imaging Laboratory in the Department of Neurology at Massachusetts General Hospital, led by Eric ... Multiple Sclerosis Imaging Laboratory. The Multiple Sclerosis (MS) Imaging Laboratory in the Department of Neurology at ... The Multiple Sclerosis (MS) Imaging Lab, directed by Eric Klawiter, MD, MSc, focuses on MS clinical research as well as the ... Corpus callosum axon diameter relates to cognitive impairment in multiple sclerosis.. Huang SY, Fan Q, Machado N, Eloyan A, ...
https://www.massgeneral.org/neurology/research/multiple-sclerosis-imaging-laboratory
Multiple sclerosis dementia
... Journal Article Overview Link to Article .mediacontainer { flex-wrap: wrap; padding: 0 !important ...
https://www.healthpartners.com/knowledgeexchange/display/document-rn20379
Cara Williams is fundraising for Multiple Sclerosis SocietyCara Williams is fundraising for Multiple Sclerosis Society
Help Cara Williams raise money to support Multiple Sclerosis Society ...
https://www.justgiving.com/fundraising/pilatesmarathon
Common treatment for multiple sclerosis may p | EurekAlert!Common treatment for multiple sclerosis may p | EurekAlert!
Common treatment for multiple sclerosis may prolong life Significant UBC study followed nearly 6,000 patients for more than two ... La Fondation pour laide à la recherche sur la sclérose en plaques, US National Multiple Sclerosis Society DOI. 10.1093/brain/ ... It was supported by the U.S. National Multiple Sclerosis Society and La Fondation pour laide à la recherche sur la sclérose en ... Common treatment for multiple sclerosis may prolong life. University of British Columbia ...
https://www.eurekalert.org/news-releases/595687
Selma Blair Reveals Multiple Sclerosis Diagnosis | Vanity FairSelma Blair Reveals Multiple Sclerosis Diagnosis | Vanity Fair
Multiple sclerosis is a chronic condition that affects the brain and/or the spinal cord and can cause vision problems, muscle ... Selma Blair Reveals Multiple Sclerosis Diagnosis. In an emotional Instagram post, the actor talks about learning she had the ... said in an Instagram post on Saturday evening that she had been diagnosed with multiple sclerosis in August. While Blair only ...
https://www.vanityfair.com/hollywood/2018/10/selma-blair-reveals-multiple-sclerosis-diagnosis
Multiple Sclerosis and Epstein-Barr VirusMultiple Sclerosis and Epstein-Barr Virus
Multiple Sclerosis Center in Maryland and the associate vice president of healthcare access for the National Multiple Sclerosis ... People with Multiple Sclerosis Say Pain Disrupts Their Daily Lives. Experts unveil research that shows the extent of pain ... Treatment for Epstein-Barr Virus May Help People With Multiple Sclerosis. By Caroline Craven on December 7, 2018 ... People with multiple sclerosis sometimes become desperate and will travel to other countries for experimental stem cell ...
https://www.healthline.com/health-news/new-immunotherapy-may-improve-ms-symptoms
New Review of Neurorehabilitation in Multiple Sclerosis - Resilience in PracticeNew Review of Neurorehabilitation in Multiple Sclerosis - Resilience in Practice
... enormous strides have been made in the efficacy and range of disease-modifying drugs for the treatment of multiple sclerosis ( ...
https://www.prnewswire.com/news-releases/new-review-of-neurorehabilitation-in-multiple-sclerosis---resilience-in-practice-645664923.html
Telemedicine for Multiple SclerosisTelemedicine for Multiple Sclerosis
If you have multiple sclerosis, learn how to get started using telemedicine for your care and how to get the most out of your ... Telemedicine and multiple sclerosis: A comprehensive literature review. J Telemed Telecare. Aug-Sep 2020;26(7-8):400-413. doi: ... Even though the COVID-19 pandemic has posed many obstacles to people living with multiple sclerosis (MS), it has also expanded ... Zissman K, Lejbkowicz I, Miller A. Telemedicine for multiple sclerosis patients: assessment using Health Value Compass. ...
https://www.verywellhealth.com/telemedicine-for-multiple-sclerosis-5092092
Natalizumab approved for multiple sclerosisNatalizumab approved for multiple sclerosis
Unknown author (‎2005)‎. Natalizumab approved for multiple sclerosis. WHO drug information 2005 ; 19(‎1)‎ : 32 https://extranet ...
https://extranet.who.int/iris/restricted/handle/10665/73312
Correlation Found Between Restless Legs Syndrome and Multiple SclerosisCorrelation Found Between Restless Legs Syndrome and Multiple Sclerosis
Framing the Conversation in Multiple Sclerosis: Considering the Role of Ethnicity and Race 0.25 CME / ABIM MOC Credits ... June 26, 2008 (Chicago, Illinois) - Patients with multiple sclerosis (MS) have more than 5 times the risk of having restless ... Correlation Found Between Restless Legs Syndrome and Multiple Sclerosis - Medscape - Jun 26, 2008. ... Framing the Conversation in Multiple Sclerosis: Considering the Role of Ethnicity and Race ...
https://www.medscape.com/viewarticle/576723
Multiple Sclerosis (MS) Symptoms, Signs, Causes, DiagnosisMultiple Sclerosis (MS) Symptoms, Signs, Causes, Diagnosis
Multiple sclerosis (MS) is an autoimmune disease that attacks nerve tissue in the brain and spinal cord. Learn the causes, ... What Is Multiple Sclerosis? MS Symptoms, Causes, Diagnosis See Slideshow What are the treatment guidelines for MS symptoms?. ... "Relapse in Multiple Sclerosis. BMJ April 14, 2015. ,https://www.bmj.com/content/350/bmj.h1765,. Luzzio, C. "Multiple Sclerosis ... What kind of disease is multiple sclerosis? See Answer From Healthy Resources. *Treatment for Secondary Progressive MS ...
https://www.rxlist.com/ms_multiple_sclerosis_symptoms_and_treatments/article.htm
Multiple sclerosis Disease Reference Guide - Drugs.comMultiple sclerosis Disease Reference Guide - Drugs.com
Multiple sclerosis In multiple sclerosis, the protective coating on nerve fibers (myelin) is damaged and may eventually be ... MRI multiple sclerosis lesions Brain MRI scan showing white lesions associated with multiple sclerosis. ... Learn more about Multiple sclerosis. *Muscle Relaxants and Alcohol Interactions. Treatment options. *Medications for Multiple ... Multiple sclerosis signs and symptoms may differ greatly from person to person and over the course of the disease depending on ...
https://www.drugs.com/mcd/multiple-sclerosis
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3...Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3...
Interpretation: For patients with first-line treatment-refractory relapsing-remitting multiple sclerosis, alemtuzumab could be ... Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 ... we enrolled adults aged 18-55 years with relapsing-remitting multiple sclerosis and at least one relapse on interferon beta or ... antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We ...
https://pubmed.ncbi.nlm.nih.gov/23122650/
multiple sclerosis | Food Safety Newsmultiple sclerosis | Food Safety News
Common Foodborne Bacteria Might Be Trigger For Multiple Sclerosis. By Dan Flynn on January 30, 2014. ... and Ann Romney are but a few of the celebrities among 400,000 Americans who were struck with multiple sclerosis…. Continue ...
https://www.foodsafetynews.com/tag/multiple-sclerosis/
Topic Multiple sclerosis - Socialinfo ViennaTopic 'Multiple sclerosis' - Socialinfo Vienna
... counselling and support for people affected by multiple sclerosis ... Multiple sclerosis. Information, counselling and support for ...
https://www.wien.gv.at/sozialinfo/content/en/10/SearchResults.do?keyword=Multiple+sclerosis&liid=11
NeurologyPatients with relapsing-remittinUsually begins in early adulthoodDiagnosis of multiple sclerosisBiomarkers in multipleAbstractNeurologistFatigueRare form of multiple sclerosisPathogenesisPediatric multiple sclerosisPrevalence of multipleDiseaseRisk of developing multipl2019TreatmentsPrimary progressiForms of multiple sclerosisModels of multiple sclerosisAdults with multiple sclerosisManagement of multiple sclerosisProgressionNational MultiplSigns and symptomsOcrelizumabDisordersInflammationTreatmentCaroline CravenAffectsExperimental autoimmune encephNeuromyelitis opticaImmuneNervous systemPeople with multipleRelapseOccurRelapsesEtiologySystematic ReviewBrainSpinalMyelinInfluenzaSymptoms of multipleSymptomLesions
Neurology6
  • The Multiple Sclerosis (MS) Imaging Laboratory in the Department of Neurology at Massachusetts General Hospital, led by Eric Klawiter, MD, MSc, is focused on developing new imaging techniques to better understand, diagnose and treat MS. (massgeneral.org)
  • Now that we know that life might be extended for people with MS who take these drugs, we do have to consider quality of life," said the study's senior author Helen Tremlett, professor in the division of neurology at UBC and the Canada Research Chair in neuroepidemiology and multiple sclerosis. (eurekalert.org)
  • The study was co-authored by Dr. Emmanuelle Leray at Ecole des Hautes Etudes en Santé Publique and Dr. Gilles Edan at the Centre Hospitalier Universitaire de Rennes in Rennes, France, and Dr. John Petkau in the department of statistics and Dr. Joel Oger and Feng Zhu in the department of medicine (neurology) at UBC. (eurekalert.org)
  • Billy Dunn, M.D., director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, said, "Multiple sclerosis can have a profound impact on a person's life. (medindia.net)
  • The low-fat diet treatment for Multiple Sclerosis was developed by Roy Swank, MD, former head of the department of Neurology at the Oregon Health & Science University. (drmcdougall.com)
  • Dr. Sarah Hopkins is an assistant professor of clinical neurology and section head for multiple sclerosis and neuro-inflammatory disorders in the division of neurology at Children's Hospital of Philadelphia. (cdc.gov)
Patients with relapsing-remittin2
  • The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. (nih.gov)
  • Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis. (drmcdougall.com)
Usually begins in early adulthood2
  • Multiple sclerosis usually begins in early adulthood, between ages 20 and 40. (medlineplus.gov)
  • Multiple sclerosis (MS) usually begins in early adulthood with an autoimmune inflammatory "strike" against components of the myelin sheath. (nature.com)
Diagnosis of multiple sclerosis4
  • Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. (medscape.com)
  • The study findings could impact a lot of people, not just because of the sheer number of patients that are on beta interferon worldwide, but also because it offers comfort in terms of our longevity--and comfort is in short supply for those with a diagnosis of multiple sclerosis," she said. (eurekalert.org)
  • What are the accepted criteria for a diagnosis of multiple sclerosis? (clevelandclinic.org)
  • 12,000 people in Washington state live with the diagnosis of Multiple Sclerosis or MS . MS is a chronic, unpredictable neurological disease that affects the brain and spinal cord. (kbcs.fm)
Biomarkers in multiple1
  • Background and Objectives: In this critical review, we explore the potential use of MRI measurements as prognostic biomarkers in multiple sclerosis (MS) patients, for both conventional measurements and more novel techniques such as magnetization transfer, diffusion tensor, and proton spectroscopy MRI. (researchgate.net)
Abstract1
  • Article abstract-Current clinical scales in multiple sclerosis (MS) are often complicated to administer, suffer from interrater variability and lack of uniform representation across grades, and are insensitive to progression at certain stages. (neurology.org)
Neurologist5
  • I'm Dr. Oliver Tobin, a neurologist specializing in multiple sclerosis at Mayo Clinic. (mayoclinic.org)
  • Multiple sclerosis is a chronic inflammatory disease of the central nervous system (brain and spinal cord)," explains Roumen Balabanov, MD, a neurologist at Northwestern Memorial Hospital in Chicago. (prevention.com)
  • A millennium later, a French neurologist, Jean-Martin Charcot, actually named the disease (sclerose en plaques) and described what later became known as Charcot's triad: nystagmus, intention tremor, and telegraphic speech. (managedcaremag.com)
  • Since diagnosing MS can be very difficult, it must be done by a neurologist who specializes in treating MS. As many as 10 percent of people diagnosed with multiple sclerosis actually have some other condition that mimics MS. (clevelandclinic.org)
  • Episode 1 - Swedish Hospital Neurologist specializing in Multiple Sclerosis, Dr. Pavle Repovic explains what MS is and why it may be more prevalent in our region than other parts of the country. (kbcs.fm)
Fatigue7
  • Multiple sclerosis is a chronic condition that affects the brain and/or the spinal cord and can cause vision problems, muscle stiffness, balance problems, fatigue, and more. (vanityfair.com)
  • Exercise therapy for fatigue in multiple sclerosis. (epnet.com)
  • Ginseng in the treatment of fatigue in multiple sclerosis: a randomized, placebo-controlled, double-blind pilot study. (epnet.com)
  • Common ones include fatigue, difficulty walking, muscle spasms, and weakness, according to the National Multiple Sclerosis Society . (self.com)
  • She conducts research evaluating the efficacy of various behavioral, exercise, and pharmacological interventions for chronic pain, depression, and/or fatigue in adults with multiple sclerosis (MS) and other acquired neurological conditions. (healthwellfoundation.org)
  • Studies of people living with multiple sclerosis have shown that exercise can help with fatigue and depression, improve strength, and result in increased participation in social activities. (nationalmssociety.org)
  • The convenience sample consisted of 26 patients diagnosed with Multiple Sclerosis enrolled in the outpatient clinic, who provided their socio-demographic data and answered fatigue scales (MFIS) and functional disability (EDSS). (bvsalud.org)
Rare form of multiple sclerosis2
  • Progressive relapsing MS is a rare form of multiple sclerosis that initially appears like primary progressive MS, with constant symptoms. (medlineplus.gov)
  • The United States Food and Drug Administration (FDA) has recently approved ocrelizumab drug for the treatment of a rare form of multiple sclerosis. (medindia.net)
Pathogenesis2
  • The pathogenesis of multiple sclerosis consists of an inflammatory and neurodegnerative phase. (nature.com)
  • INTRODUCTION: At what stage in the pathogenesis of multiple sclerosis (MS) does the damage to axons occur, and why should there be any axon loss at all in what is thought to be principally an axon sparing demyelinating disease? (ox.ac.uk)
Pediatric multiple sclerosis5
  • In general, atypical features of pediatric multiple sclerosis (MS) include fever, encephalopathy, progressive symptoms or disease course, other organ system involvement (including the peripheral nervous system), absence of CSF OCBs, elevated IgG index, and markedly elevated CSF leukocytes. (medscape.com)
  • Waubant E, Chabas D. Pediatric multiple sclerosis. (medscape.com)
  • Consensus definitions proposed for pediatric multiple sclerosis and related disorders. (medscape.com)
  • International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. (medscape.com)
  • The Partners Pediatric Multiple Sclerosis Center at the Massachusetts General Hospital for Children is dedicated to the care of children and adolescents with Multiple Sclerosis and related demyelinating disorders such as neuromyelitis optica (NMO) and acute disseminated encephalomyelitis (ADEM). (brighammscenter.org)
Prevalence of multiple1
  • Estimates from individual provinces suggest that the prevalence of multiple sclerosis (MS) among Canadians may be one of the highest in the world. (gc.ca)
Disease38
  • Baló concentric sclerosis is considered by some authors to be a variant of Schilder disease, with MRI lesions showing a characteristic alternating pattern of spared and damaged white matter that suggests progression of the disease process from the ventricles outward. (medscape.com)
  • Neurodegeneration is the correlate of disease progression in multiple sclerosis (MS) and thus biological biomarkers that sensitively reflect this process are much needed. (nih.gov)
  • Steinman, L. Multiple sclerosis: a two-stage disease. (nature.com)
  • Published recently in European Neurological Review the peer-reviewed journal from touchNEUROLOGY, Professor Kesselring stresses that although enormous strides have been made in the efficacy and range of disease-modifying drugs for the treatment of multiple sclerosis (MS) there is another equally important concept that is neurorehabilitation. (prnewswire.com)
  • Multiple sclerosis ( MS ) is an autoimmune disease in which the immune system attacks myelinated axons in the brain and spinal cord nerve fibers ( central nervous system ), damaging or destroying the myelin ( demyelination ) and/or the axons (nerve tissue). (rxlist.com)
  • What kind of disease is multiple sclerosis? (rxlist.com)
  • Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). (drugs.com)
  • Multiple sclerosis signs and symptoms may differ greatly from person to person and over the course of the disease depending on the location of affected nerve fibers. (drugs.com)
  • Multiple Sclerosis (MS) is a chronic neurological disease that affects the central nervous system (CNS)-the brain, spinal cord and optic nerves. (caregiver.org)
  • Multiple sclerosis (MS) is a chronic degenerative autoimmune disease of the central nervous system. (uoc.edu)
  • Multiple sclerosis is a disease that affects the spinal cord and brain. (epnet.com)
  • A systematic review and meta-analysis of strength training in individuals with multiple sclerosis or Parkinson disease. (epnet.com)
  • Pasithea Therapeutics announced encouraging preclinical results that support the efficacy of a tolerizing, inverse DNA vaccine for multiple sclerosis (MS). Based on experiments conducted on the EAE mouse model, Pasithea reported that intramuscular injections of the candidate vaccine (PAS002) delayed the onset of paralysis and reduced severity of peak disease. (genengnews.com)
  • Joni Bell, who has practiced Qigong for 10 years, says "I've had multiple sclerosis for 32 years and I was compromised by the disease. (selfgrowth.com)
  • One major focus has been to study the effect of pharmacotherapies on adaptive immune responses in the human inflammatory disease multiple sclerosis (MS), and its model experimental autoimmune encephalomyelitis (EAE). (utsouthwestern.edu)
  • There is an ongoing effort to translate observations made in the laboratory to the bedside, and clinical trials in MS, amyotrophic lateral sclerosis, and Alzheimer disease (AD) have served that goal. (utsouthwestern.edu)
  • According to the Centers for Disease Control and Prevention, around 15% of patients have primary progressive multiple sclerosis. (medindia.net)
  • Multiple sclerosis is a chronic, autoimmune disease of the central nervous system found to disrupt the communication between the brain and the other parts of the body. (medindia.net)
  • Given this hard look at the reality of Multiple Sclerosis, more people would be interested in a treatment that is cost-free, side-effect-free and stops the disease in over 90% of those people with early disease. (drmcdougall.com)
  • Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS), and it remains the most common immune-mediated disorder affecting the CNS. (springer.com)
  • This points to a potential target for developing new therapies to treat multiple sclerosis and could have important implications for other autoimmune diseases, such as the colon disease colitis and the chronic skin condition atopic dermatitis. (news-medical.net)
  • Multiple sclerosis, often called MS, is a disease that gradually destroys the protective covering of nerve cells in the brain and spinal cord. (kaiserpermanente.org)
  • Women with multiple sclerosis (MS) may face challenges related to managing reproduction, pregnancy, and menopause while simultaneously managing their disease. (frontiersin.org)
  • Two decades of clinical experience with immunomodulatory treatments for multiple sclerosis point to distinct immunological pathways that drive disease relapses and progression. (ox.ac.uk)
  • In light of this, we discuss our current understanding of multiple sclerosis immunopathology, evaluate long-standing hypotheses regarding the role of the immune system in the disease and delineate key questions that are still unanswered. (ox.ac.uk)
  • Less than twenty years ago, people with multiple sclerosis had to fight for a decision from their medical practitioners, unless they were very advanced in the disease. (fibromyalgia-symptoms.org)
  • Multiple sclerosis (SM) is a disease caused by a malfunction of the immune system, where instead of defending the body, it attacks it instead. (futurism.com)
  • Multiple sclerosis (MS) is a nervous system disease that affects the brain, optic nerve (which helps. (medlineplus.gov)
  • An estimated 2.3 million people worldwide live with Multiple Sclerosis (MS). MS is a hard-to-predict disease of the central nervous system. (medlineplus.gov)
  • Multiple sclerosis, or MS, is a widespread and oftentimes disabling neurological disease that af. (girlwithms.com)
  • Multiple sclerosis (MS) is a chronic progressive neurological disease and the majority of patients will experience some degree of impaired mobility. (biomedcentral.com)
  • Would They Help Lessen Multiple Sclerosis Or Liver Disease C? (beachmagazine.info)
  • The Health Care Great Things About Cannabinoids - Would They Help Lessen Multiple Sclerosis Or Liver Disease C? (beachmagazine.info)
  • The Multiple sclerosis is a demyelinating neurological disease of the central nervous system that mainly affects young women. (bvsalud.org)
  • Multiple sclerosis is a chronic inflammatory, demyelinating, and neurodegenerative disease of the central nervous system and a common cause of disability in young adults . (bvsalud.org)
  • Multiple sclerosis is a demyelinating disease of the CNS. (medscape.com)
  • This disease is discussed in detail in the relevant article (see Multiple Sclerosis ). (medscape.com)
  • Health-related qualify of life (HRQOL) is being increasingly recognized as an important outcome in the health sciences, especially in relation to chronic diseases such as multiple sclerosis (MS). One of the main shortcomings in the field is the lack of instruments designed to simultaneously assess specific aspects pertaining to each disease and general questions, which would allow comparisons to be made between different nosological entities. (bvsalud.org)
Risk of developing multipl1
  • Other factors associated with an increased risk of developing multiple sclerosis include changes in the IL7R gene and environmental factors, such as exposure to the Epstein-Barr virus, low levels of vitamin D, and smoking. (medlineplus.gov)
20191
  • Welcome to the 2019 Annual Meeting of the Consortium of Multiple Sclerosis Centers. (confex.com)
Treatments2
  • Too few people are told that within 10 years of diagnosis, even with the best treatments available, nearly half of those with Multiple Sclerosis will be wheelchair bound, bedridden, or dead. (drmcdougall.com)
  • Patients need to speak with their physician about current or future use of medications that affect the immune system, including other treatments for multiple sclerosis. (ivxhealth.com)
Primary progressi2
  • The findings of the drug showed that the progression of primary progressive multiple sclerosis was slowed down by 24% when compared with placebo. (medindia.net)
  • There is no specific treatment for primary progressive multiple sclerosis and the drug is found to reduce relapse rates and the worsening of disability when compared to other drugs. (medindia.net)
Forms of multiple sclerosis3
  • There are several forms of multiple sclerosis: relapsing-remitting MS, secondary progressive MS, primary progressive MS, and progressive relapsing MS. The most common is the relapsing-remitting form, which affects approximately 80 percent of people with multiple sclerosis. (medlineplus.gov)
  • Teriflunomide is a pyrimi-dine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis. (managedcaremag.com)
  • Ocrevus IV infusion treatment is approved for treating certain forms of multiple sclerosis . (ivxhealth.com)
Models of multiple sclerosis2
  • In addition, cold suppresses T-cell priming and pathogenicity against the body's own antigens through the modulation of monocytes, thereby reducing neuroinflammation in mouse models of multiple sclerosis. (genengnews.com)
  • Further, the work has produced new research models of multiple sclerosis symptoms such as movement disorders and balance control problems that have, until now, resisted efforts to mimic them effectively in the lab. (news-medical.net)
Adults with multiple sclerosis1
  • Exercise as a therapy for improvement of walking ability in adults with multiple sclerosis: a meta-analysis. (epnet.com)
Management of multiple sclerosis2
  • The system is not yet sufficiently integrated to enable data to be shared between everyone involved in the management of multiple sclerosis, or any other pathology,' said Carrion . (uoc.edu)
  • Vitamin D for the management of multiple sclerosis. (epnet.com)
Progression3
  • Baló concentric sclerosis is often associated with more inflammatory cerebrospinal fluid (CSF) findings and a more fulminant progression than typical MS. (medscape.com)
  • Multiple sclerosis is a nervous disorder, new drug called ocrelizumab found to reduce attacks and symptom progression in patients. (medindia.net)
  • I recently came across the following information about more recent research about Multiple Sclerosis mylein , that there is an enzyme that when reduced can slow the progression of Multiple Sclerosis in mice. (blogspot.com)
National Multipl8
  • About 80% of people in the early stages of MS have unexplained muscle weakness, which usually starts in the legs, according to the National Multiple Sclerosis Society . (prevention.com)
  • According to the National Multiple Sclerosis Society (NMSS) , the risks of surgery and anesthesia are the same for people with MS and people without MS. However, other aspects of surgery, such as the recovery process, may be more challenging for those with symptoms such as muscle weakness. (medicalnewstoday.com)
  • It was supported by the U.S. National Multiple Sclerosis Society and La Fondation pour l'aide à la recherche sur la sclérose en plaques. (eurekalert.org)
  • This is very early but exciting and promising," said Kathy Costello, a nurse practitioner at the Johns Hopkins Multiple Sclerosis Center in Maryland and the associate vice president of healthcare access for the National Multiple Sclerosis Society. (healthline.com)
  • According to the National Multiple Sclerosis Society (NMSS), fewer than 5,000 children and teens are living with the condition in the United States, and fewer than 10,000 have it worldwide. (everydayhealth.com)
  • 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935. (nationalmssociety.org)
  • We have been selected as one of twelve regional Pediatric MS Centers of Excellence by the National Multiple Sclerosis Society, and we work with the other Centers and the National Multiple Sclerosis Society as part of a network to provide comprehensive care and to conduct clinical research related to childhood multiple sclerosis. (brighammscenter.org)
  • The study was funded by the National Institutes of Health, the Christopher and Dana Reeves Paralysis Foundation, and the National Multiple Sclerosis Society. (blogspot.com)
Signs and symptoms2
  • What are multiple sclerosis (MS) signs and symptoms? (rxlist.com)
  • Fast Five Quiz: Multiple Sclerosis Signs and Symptoms - Medscape - Jan 05, 2021. (medscape.com)
Ocrelizumab4
  • Ocrelizumab drug targets B cells and shows promising results for the treatment of multiple sclerosis. (medindia.net)
  • Ocrevus (ocrelizumab) is an immunosuppressive drug that physicians prescribe for patients with certain kinds of multiple sclerosis (MS). (ivxhealth.com)
  • Case Report: Rapid Desensitization to Ocrelizumab for Multiple Sclerosis Is Effective and Safe. (bvsalud.org)
  • Ocrelizumab is a recombinant humanized monoclonal antibody that targets CD20-positive B cells and has been approved in the treatment of multiple sclerosis . (bvsalud.org)
Disorders2
  • Multiple Sclerosis is one of the most common neurological disorders leading to disability. (novapublishers.com)
  • It has been identified in newborns and it has been associated with pediatric disorders of neurodevelopment since more than 15 years, mainly associated with benign epilepsy, febrile seizures, meningoencephalitis, meningitis, encephalitis and multiple sclerosis. (bvsalud.org)
Inflammation5
  • Sclerosis means abnormal hardening or thickening of tissue, often due to inflammation. (rxlist.com)
  • Examples of other conditions that masquerade as MS include inflammation in the blood vessels, multiple strokes , vitamin deficiency, and brain infection. (clevelandclinic.org)
  • Multiple sclerosis (MS) is a CNS disorder characterized by inflammation, demyelination and neurodegeneration, and is the most common cause of acquired nontraumatic neurological disability in young adults. (researchgate.net)
  • New research into the causes of the excessive inflammation that drives multiple sclerosis has identified a faulty 'brake' within immune cells, a brake that should be controlling the inflammation. (news-medical.net)
  • To the researchers' surprise, the resulting inflammation did not produce the paralysis often associated with multiple sclerosis. (news-medical.net)
Treatment12
  • Australian scientists say they've found a new immunotherapy that's showing promise as a treatment for multiple sclerosis. (healthline.com)
  • For patients with first-line treatment-refractory relapsing-remitting multiple sclerosis, alemtuzumab could be used to reduce relapse rates and sustained accumulation of disability. (nih.gov)
  • Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis. (epnet.com)
  • A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis. (epnet.com)
  • Is there a dietary treatment for multiple sclerosis? (longreads.com)
  • The 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) took place in Amsterdam from 26th to 28th October, and was attended by Dr. John. (msnz.org.nz)
  • If you have multiple sclerosis and would like to learn more about Ocrevus treatment options, find an Ocrevus infusion center in your area here . (ivxhealth.com)
  • A number of new, highly effective drugs for relapsing-remitting multiple sclerosis have recently turned the treatment paradigm in multiple sclerosis (MS) upside down. (medscape.com)
  • Despite the unprecedented efficacy results of monoclonal antibodies in patients with multiple sclerosis (MS), infusion reactions inherent to their mechanism of action and the intravenous route of administration may lead to treatment discontinuation. (medscape.com)
  • The research in this area may show some promise in developing a therapy or treatment that may be able to help reduce the Multiple Sclerosis mylein effects and damage, as well as the severe effects of Multiple Sclerosis on the body. (blogspot.com)
  • Although mechanisms involved in the response were not elucidated, the procedure occurred uneventfully and permitted first-line multiple sclerosis treatment maintenances . (bvsalud.org)
  • It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews. (bvsalud.org)
Caroline Craven1
  • Caroline Craven - Certified Life Coach, MS Advocate, Motivational Speaker, Writer & Patient Expert living with Multiple Sclerosis. (girlwithms.com)
Affects3
  • Multiple sclerosis, a debilitating immune disorder that affects the brain and spinal cord, was probably first described around 1200 in a young Icelandic woman named Halldora who suddenly lost her vision and mobility but recovered a week later, a common initial presentation of MS. (managedcaremag.com)
  • Multiple sclerosis is a neurological disorder, which affects thousands of people and commonly women in the United States. (medindia.net)
  • And, interestingly, the therapeutic nature of music can also be harnessed to help manage chronic neurological diseases, like multiple sclerosis (MS), which affects nearly 1 million people in the United States. (wtkr.com)
Experimental autoimmune enceph1
  • Multiple sclerosis (MS) and the animal model of MS, experimental autoimmune encephalomyelitis (EAE), are autoimmune demyelinating diseases of the central nervous system (CNS) characterized by the development of myelin-reactive CD4 T cells, Th1, Th17, T reg , γδ T cells and B cells (Fig. 1 ). (springer.com)
Neuromyelitis optica1
  • Serum markers, plasma markers and B cells from participants are isolated and utilized to understand the basic biology of multiple sclerosis, transverse myelitis, neuromyelitis optica and autoimmune encephalitis. (utsouthwestern.edu)
Immune4
  • Multiple sclerosis is a disorder in which the body's immune system attacks the protective covering of the nerve cells in the brain, optic nerve and spinal cord, called the myelin sheath. (mayoclinic.org)
  • Multiple Sclerosis is a condition where one's immune system dysfunctionally attacks the fatty sheath that insulates nerves. (selfgrowth.com)
  • Multiple myeloma (MM) is an incurable cancer in which uncontrolled plasma cell proliferation disrupts the bone marrow environment and impairs immune function. (hrb.ie)
  • Background: Low exposure to ultraviolet radiation (UVR) from sunlight may be a risk factor for developing multiple sclerosis (MS). Possible pathways may be related to effects on immune system function or vitamin D insufficiency, as UVR plays a role in the production of the active form of vitamin D in the body. (cdc.gov)
Nervous system3
  • In multiple sclerosis, the protective coating on nerve fibers (myelin) in the central nervous system is damaged. (drugs.com)
  • Multiple sclerosis (MS) , a condition of the central nervous system (CNS) that can cause muscle weakness and sensory symptoms (including, for example, vision loss), is usually diagnosed in adults. (everydayhealth.com)
  • In multiple sclerosis, damage to the myelin in the central nervous system (CNS) - and to the nerve fibers themselves - interferes with the transmission of nerve signals between the brain and spinal cord and other parts of the body. (nationalmssociety.org)
People with multiple11
  • Problems with muscle control are common in people with multiple sclerosis. (medlineplus.gov)
  • Primary progressive MS is the next most common form, affecting approximately 10 to 20 percent of people with multiple sclerosis. (medlineplus.gov)
  • The effect of exercise, yoga and physiotherapy on the quality of life of people with multiple sclerosis: Systematic review and meta-analysis. (epnet.com)
  • Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews. (epnet.com)
  • In a study investigating the effectiveness of mindful movement in symptom management in people with multiple sclerosis, investigators noticed a broad improvement in symptomatology in practitioners of these arts while the control group showed a continued deterioration in symptoms. (selfgrowth.com)
  • The study concluded that "training in mindfulness of movement appeared to result in improved symptom management for…people with multiple sclerosis. (selfgrowth.com)
  • I have been training people with multiple sclerosis (MS) for more than 10 years now and have personally worked with many who join the 12-week challenge that I hold locally through the MS Fitness Challenge charity. (everydayhealth.com)
  • We are conducting a study among people with Multiple Sclerosis to understand the impact of their condition on their quality of life and how it impacts their day-to-day decisions making. (girlwithms.com)
  • Many people with multiple sclerosis develop neurogenic lower urinary tract dysfunction. (wellspect.com)
  • A new study shows that kidney changes occur among people with multiple sclerosis, and decreased kidney function is seen in about 3% of patients. (wellspect.com)
  • This suggests that proactive monitoring and control of bladder function among people with multiple sclerosis is warranted. (wellspect.com)
Relapse3
  • Although some people may worry that anesthesia could worsen their multiple sclerosis (MS) symptoms or bring on a relapse, there is no evidence to suggest that this is true. (medicalnewstoday.com)
  • In our 2 year, rater-masked, randomised controlled phase 3 trial, we enrolled adults aged 18-55 years with relapsing-remitting multiple sclerosis and at least one relapse on interferon beta or glatiramer. (nih.gov)
  • The relapse rates of multiple sclerosis showed 46% drop in annual relapse rates when compared to other drugs like interferon. (medindia.net)
Occur3
  • Multiple sclerosis is most commonly diagnosed in females ages 20 to 40 but may occur at any age and both genders. (rxlist.com)
  • Symptoms of multiple sclerosis usually occur between the age of 20 and 40 years. (medindia.net)
  • The condition may occur secondary to a disorder or trauma, such as a tumor, a stroke, multiple sclerosis (MS), cerebral palsy , or a spinal cord , brain , or peripheral nerve injury . (medscape.com)
Relapses1
  • Around 48% of the patients in the relapsing- remitting multiple sclerosis had no relapses and had no worsening symptoms of neurological symptoms. (medindia.net)
Etiology1
  • There is still no conclusive etiology for Multiple Sclerosis, though statistically the group at greatest risk consists of Caucasian women born in the northern United States. (selfgrowth.com)
Systematic Review2
  • Physical activity and disability outcomes in multiple sclerosis: A systematic review (2011-2016). (epnet.com)
  • Physiotherapy Rehabilitation for People With Progressive Multiple Sclerosis: A Systematic Review. (epnet.com)
Brain2
  • The overall goal of this study is to elucidate a mechanism by which vancomycin modulates the gut-brain axis in multiple sclerosis (MS). The gut microbiome plays an important role in autoimmunity, including MS. However, the identity of gut microbes modulating neuroinflammation in MS and their mechanisms of action remain obscure. (clinicaltrials.gov)
  • Multiple sclerosis (MS) is aptly named for the many scars it produces in the brain and spinal cord. (altmedrev.com)
Spinal4
  • Clinicians who specialize in MS commonly see patients referred for multiple, ill-defined, vague complaints and T2 hyperintense lesions on recent head or spinal magnetic resonance imaging (MRI) scans. (medscape.com)
  • spinal cord injury, spina bifida, and multiple sclerosis. (wellspect.com)
  • Science Alert: Neurogenic lower urinary tract dysfunction from 3 perspectives - spinal cord injury, spina bifida, and multiple sclerosis. (wellspect.com)
  • One common reason behind lower urinary tract dysfunction is neurological damage secondary to spinal cord injury (SCI), spina bifida, or multiple sclerosis. (wellspect.com)
Myelin4
  • Think of myelin as a conduit in an electrical system that ensures messages sent by axons (nerve fibers) are not lost en route. (rxlist.com)
  • In multiple sclerosis, the protective coating on nerve fibers (myelin) is damaged and may eventually be destroyed. (drugs.com)
  • Guggenmos J, Schubart AS, Ogg S, Andersson M, Olsson T, Mather IH, Linington C. Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. (drmcdougall.com)
  • 30, 2012) - Researchers studying Multiple Sclerosis (MS) have long been looking for the specific molecules in the body that cause lesions in myelin, the fatty, insulating cells that sheathe the nerves. (blogspot.com)
Influenza1
  • To investigate a potential risk for multiple sclerosis (MS) after vaccination with Arepanrix, the GlaxoSmithKline AS03-adjuvanted influenza A(H1N1)pdm09 vaccine, we used the provincewide immunization registry for Manitoba, Canada, to match 341,347 persons vaccinated during the 2009 pandemic to 485,941 unvaccinated persons on age, sex, address, and a propensity score measuring the probability of vaccination. (cdc.gov)
Symptoms of multiple6
  • Firstly, are there typical symptoms of multiple sclerosis? (mayoclinic.org)
  • The early signs and early symptoms of multiple sclerosis usually begin between the ages of 20 and 40 years old. (rxlist.com)
  • Providing Information on ways for Taming Symptoms of Multiple Sclerosis, using Alternative and Natural Ways! (blogspot.com)
  • Please Note: All sponsored links listed on this Blog lead to information, services or products that the author has used in the past or is currently using that has helped her to find relief to one or more of her symptoms of Multiple Sclerosis. (blogspot.com)
  • The information or products or services described or provided through the additional links is provided to you in the hopes that these products or services may be able to help you to find relief to your symptoms of Multiple Sclerosis also. (blogspot.com)
  • The Taming Symptoms of Multiple Sclerosis Blog or MS Blog is a place for those that have been diagnosed with Multiple Sclerosis to discuss whatever is on your mind about your symptoms, your struggles and your tips on what you have found that has helped bring relief to your Multiple Sclerosis symptoms . (blogspot.com)
Symptom1
  • However, many children who have experienced at least one symptom suggestive of multiple sclerosis may be misdiagnosed because their MS is mistaken for another neurological disorder that's more common in children, such as acute disseminated encephalomyelitis (ADEM), notes the NMSS. (everydayhealth.com)
Lesions2
  • The resulting damage leaves lesions or scars, and this is where the name comes from: multiple sclerosis, multiple scars. (mayoclinic.org)
  • Cognitive impairment and the regional distribution of cerebellar lesions in multiple sclerosis. (massgeneral.org)
ORANGE RIBBON FOR LEUKEMIA AND MULTIPLE SCLEROSIS AWARENESS PATCH | eBay
ORANGE RIBBON FOR LEUKEMIA AND MULTIPLE SCLEROSIS AWARENESS PATCH | eBay (ebay.com)
Multiple Sclerosis Foundation - Grants & Programs
Multiple Sclerosis Foundation - Grants & Programs (msfocus.org)
Rare program for multiple sclerosis patients set to grow
Rare program for multiple sclerosis patients set to grow (desertsun.com)
Collaboration Seeks To Develop Multiple Sclerosis Diagnostic Test | Medical Product Outsourcing
Collaboration Seeks To Develop Multiple Sclerosis Diagnostic Test | Medical Product Outsourcing (mpo-mag.com)
PwMS of the Year 2017 Application Form 2017 Word Doc | Multiple Sclerosis Society of NZMultiple Sclerosis Society of NZ
PwMS of the Year 2017 Application Form 2017 Word Doc | Multiple Sclerosis Society of NZMultiple Sclerosis Society of NZ (msnz.org.nz)
EDM image | Multiple Sclerosis Society of NZMultiple Sclerosis Society of NZ
EDM image | Multiple Sclerosis Society of NZMultiple Sclerosis Society of NZ (msnz.org.nz)
Tai Chi | Multiple Sclerosis Society of NZMultiple Sclerosis Society of NZ
Tai Chi | Multiple Sclerosis Society of NZMultiple Sclerosis Society of NZ (msnz.org.nz)
Covid antiviral medication | Multiple Sclerosis Society of NZMultiple Sclerosis Society of NZ
Covid antiviral medication | Multiple Sclerosis Society of NZMultiple Sclerosis Society of NZ (msnz.org.nz)
Bronwyn Hutchinson View from my apt window in Mexico | Multiple Sclerosis Society of NZMultiple Sclerosis Society of NZ
Bronwyn Hutchinson View from my apt window in Mexico | Multiple Sclerosis Society of NZMultiple Sclerosis Society of NZ (msnz.org.nz)
Multiple Sclerosis Society of Canada - Faire un don
Multiple Sclerosis Society of Canada - Faire un don (msspwcms.donordrive.com)
A randomised controlled study of Sativex® in patients with symptoms of spasticity due to multiple sclerosis
A randomised controlled study of Sativex® in patients with symptoms of spasticity due to multiple sclerosis (epistemonikos.org)
NOMS PMRs - Industry and Occupation - NIOSH Workplace Safety and Health Topic: National Occupational Mortality Surveillance ...
NOMS PMRs - Industry and Occupation - NIOSH Workplace Safety and Health Topic: National Occupational Mortality Surveillance ... (cdc.gov)
NOMS PMRs - Industry and Occupation - NIOSH Workplace Safety and Health Topic: National Occupational Mortality Surveillance ...
NOMS PMRs - Industry and Occupation - NIOSH Workplace Safety and Health Topic: National Occupational Mortality Surveillance ... (cdc.gov)
NOMS PMRs - Industry and Occupation - NIOSH Workplace Safety and Health Topic: National Occupational Mortality Surveillance ...
NOMS PMRs - Industry and Occupation - NIOSH Workplace Safety and Health Topic: National Occupational Mortality Surveillance ... (cdc.gov)
NOMS PMRs - Industry and Occupation - NIOSH Workplace Safety and Health Topic: National Occupational Mortality Surveillance ...
NOMS PMRs - Industry and Occupation - NIOSH Workplace Safety and Health Topic: National Occupational Mortality Surveillance ... (cdc.gov)
NOMS PMRs - Industry and Occupation - NIOSH Workplace Safety and Health Topic: National Occupational Mortality Surveillance ...
NOMS PMRs - Industry and Occupation - NIOSH Workplace Safety and Health Topic: National Occupational Mortality Surveillance ... (cdc.gov)
NOMS PMRs - Industry and Occupation - NIOSH Workplace Safety and Health Topic: National Occupational Mortality Surveillance ...
NOMS PMRs - Industry and Occupation - NIOSH Workplace Safety and Health Topic: National Occupational Mortality Surveillance ... (cdc.gov)
NOMS PMRs - Industry and Occupation - NIOSH Workplace Safety and Health Topic: National Occupational Mortality Surveillance ...
NOMS PMRs - Industry and Occupation - NIOSH Workplace Safety and Health Topic: National Occupational Mortality Surveillance ... (cdc.gov)
Cms-admin, Author at Fibromyalgia Symptoms
Cms-admin, Author at Fibromyalgia Symptoms (fibromyalgia-symptoms.org)
IL7R gene: MedlinePlus Genetics
IL7R gene: MedlinePlus Genetics (medlineplus.gov)
Spasticity: Practice Essentials, Background, Pathophysiology
Spasticity: Practice Essentials, Background, Pathophysiology (medscape.com)
Central Vertigo: Background, Pathophysiology, Epidemiology
Central Vertigo: Background, Pathophysiology, Epidemiology (medscape.com)
Clinical Applications of Somatosensory Evoked Potentials: Overview, Clinical Interpretation, Clinical Uses
Clinical Applications of Somatosensory Evoked Potentials: Overview, Clinical Interpretation, Clinical Uses (medscape.com)
Multiple Sclerosis: Practice Essentials, Background, Pathophysiology
Multiple Sclerosis: Practice Essentials, Background, Pathophysiology (medscape.com)
Our Community, Our Health: Multiple Sclerosis
Our Community, Our Health: Multiple Sclerosis (mediasite.video.ufl.edu)
Dr. Terry Wahls on Her Recovery From Multiple Sclerosis
Dr. Terry Wahls on Her Recovery From Multiple Sclerosis (a4m.com)
Artículos destacados Multiple Sclerosis | NIH MedlinePlus Revista
Artículos destacados Multiple Sclerosis | NIH MedlinePlus Revista (magazine.medlineplus.gov)
Multiple Sclerosis
Multiple Sclerosis (fmrif.nimh.nih.gov)
CNS Causes of Vertigo Clinical Presentation: History, Physical, Causes
CNS Causes of Vertigo Clinical Presentation: History, Physical, Causes (medscape.com)
Multiple Sclerosis | National Institute of Neurological Disorders and Stroke
Multiple Sclerosis | National Institute of Neurological Disorders and Stroke (ninds.nih.gov)
Childhood Optic Neuritis: Practice Essentials, Background, Pathophysiology
Childhood Optic Neuritis: Practice Essentials, Background, Pathophysiology (medscape.com)
A Round-Up of Seven New Neurology Studies
A Round-Up of Seven New Neurology Studies (medscape.com)
Therapeutic Exercise: Overview, Physiologic Aspects of Physical Fitness, Medical Evaluation
Therapeutic Exercise: Overview, Physiologic Aspects of Physical Fitness, Medical Evaluation (medscape.com)
Clinical Applications of Somatosensory Evoked Potentials: Overview, Clinical Interpretation, Clinical Uses
Clinical Applications of Somatosensory Evoked Potentials: Overview, Clinical Interpretation, Clinical Uses (medscape.com)